KINDAI UNIVERSITY


※苗字と名前の間にスペースをあけ、入力してください

髙田 充隆タカダ ミツタカ

プロフィール

所属部署名薬学部 医療薬学科 / 薬学研究科
職名教授
学位博士(薬学)
専門医薬品情報科学
ジャンル医療・健康/薬と社会
コメンテータガイドhttp://www.kindai.ac.jp/meikan/794-takada-mitsutaka.html
ホームページURL
メールアドレス
Last Updated :2018/12/01

コミュニケーション情報 byコメンテータガイド

コメント

    日々蓄積されている医療関連情報データベースを活用して、データマイニングの手法を用い、医薬品による未知の副作用や有効性について研究しています。

報道関連出演・掲載一覧

    <報道関連出演・掲載一覧>
    ●2018/8/28
    NHK「ニュース」
    「ドラッグ・リポジショニン」について。

    ●2015/12/1
     テレビ朝日「グッド!モーニング」
     薬の別の病気に対する効用について。

研究活動情報

論文

  • Gastrointestinal risk factors and prescribing pattern of antiulcer agents in patients taking low-dose aspirin in Japan., Iwasawa M, Wada K, Takada M, The International journal of pharmacy practice, 26, 4, 369, 372,   2018年08月, 査読有り
  • Effects of vitamin K epoxide reductase complex 1 gene polymorphisms on warfarin control in Japanese patients with left ventricular assist devices (LVAD)., Nakagita K, Wada K, Mukai Y, Uno T, Nishino R, Matsuda S, Takenaka H, Terakawa N, Oita A, Takada M, European journal of clinical pharmacology, 74, 7, 885, 894,   2018年07月, 査読有り
  • Effect of fluconazole on the pharmacokinetics of everolimus and tacrolimus in a heart transplant recipient: Case report., Nakagita K, Wada K, Terada Y, Matsuda S, Terakawa N, Oita A, Takada M, International journal of clinical pharmacology and therapeutics, 56, 6, 270, 276,   2018年06月, 査読有り
  • Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients., Uno T, Wada K, Matsuda S, Terada Y, Oita A, Kawase A, Takada M, European journal of drug metabolism and pharmacokinetics,   2018年04月, 査読有り
  • Use of rifabutin to treat tuberculosis in a cardiac transplant recipient: A case report
., Takayoshi M, Wada K, Terada Y, Matsuda S, Nakagita K, Oita A, Takada M, Shionoiri A, Sunami H, Nakajima S, Kuroda K, Sato T, Seguchi O, Yanase M, Fukushima N, International journal of clinical pharmacology and therapeutics, 56, 4, 184, 188,   2018年04月, 査読有り
  • Association between Serum Amiodarone and N-Desethylamiodarone Concentrations and Development of Thyroid Dysfunction., Yamato M, Wada K, Hayashi T, Fujimoto M, Hosomi K, Oita A, Takada M, Clinical drug investigation, 38, 1, 39, 48,   2018年01月, 査読有り
  • The influence of residual apixaban on bleeding complications during and after catheter ablation of atrial fibrillation., Mukai Y, Wada K, Miyamoto K, Nakagita K, Fujimoto M, Hosomi K, Kuwahara T, Takada M, Kusano K, Oita A, Journal of arrhythmia, 33, 5, 434, 439,   2017年10月, 査読有り
  • Response: Amiodarone-induced thyroid dysfunction and a perturbed N-desethyl-amiodarone to amiodarone ratio; could a drug-induced toxicity be regulating exposure to the offending agent?, Takada M, Yamato M, Wada K, Fujimoto M, Hosomi K, Hayashi T, Oita A, European journal of clinical pharmacology, 73, 8, 1053, 1054,   2017年08月, 査読有り
  • Angiotensin receptor blockers and the risk of cancer: data mining of a spontaneous reporting database and a claims database
., Fujimoto M, Kanou M, Hosomi K, Takada M, International journal of clinical pharmacology and therapeutics, 55, 4, 295, 303,   2017年04月, 査読有り
  • Association between N-desethylamiodarone/amiodarone ratio and amiodarone-induced thyroid dysfunction., Yamato M, Wada K, Fujimoto M, Hosomi K, Hayashi T, Oita A, Takada M, European journal of clinical pharmacology, 73, 3, 289, 296,   2017年03月, 査読有り
  • Circadian pharmacokinetics and limited sampling strategy of everolimus in heart transplant patients
., Terada Y, Wada K, Matsuda S, Kuwahara T, Kawabata A, Takada M, Watanabe T, Nakajima S, Sato T, Seguchi O, Yanase M, Fukushima N, Nakatani T, International journal of clinical pharmacology and therapeutics, 55, 1, 1, 8,   2017年01月, 査読有り
  • Tacrolimus Triggers Transient Receptor Potential Vanilloid-1-Dependent Relapse of Pancreatitis-Related Pain in Mice., Terada Y, Tsubota M, Sugo H, Wakitani K, Sekiguchi F, Wada K, Takada M, Oita A, Kawabata A, Pharmacology, 99, 5-6, 281, 285,   2017年, 査読有り
  • Risk factors for amiodarone-induced thyroid dysfunction in Japan., Kinoshita S, Hayashi T, Wada K, Yamato M, Kuwahara T, Anzai T, Fujimoto M, Hosomi K, Takada M, Journal of arrhythmia, 32, 6, 480, 480,   2016年12月, 査読有り
  • Long-term impact of therapeutic drug monitoring on the risk of hypoglycemia in HOCM patients on cibenzoline therapy
., Mukai Y, Wada K, Fujimoto M, Hosomi K, Kuwahara T, Takada M, International journal of clinical pharmacology and therapeutics, 54, 10, 795, 803,   2016年10月, 査読有り
  • Association between Benzodiazepine Use and Dementia: Data Mining of Different Medical Databases., Takada M, Fujimoto M, Hosomi K, International journal of medical sciences, 13, 11, 825, 834,   2016年, 査読有り
  • Interaction between Warfarin and Linezolid in Patients with Left Ventricular Assist System in Japan., Kinoshita S, Wada K, Matsuda S, Kuwahara T, Sunami H, Sato T, Seguchi O, Yanase M, Nakatani T, Takada M, Internal medicine (Tokyo, Japan), 55, 7, 724, 724,   2016年, 査読有り
  • Inverse Association between Sodium Channel-Blocking Antiepileptic Drug Use and Cancer: Data Mining of Spontaneous Reporting and Claims Databases., Takada M, Fujimoto M, Motomura H, Hosomi K, International journal of medical sciences, 13, 1, 48, 59,   2016年, 査読有り
  • Association between statin use and cancer: data mining of a spontaneous reporting database and a claims database., Fujimoto M, Higuchi T, Hosomi K, Takada M, International journal of medical sciences, 12, 3, 223, 233,   2015年, 査読有り
  • Association of statin use with storage lower urinary tract symptoms (LUTS): data mining of prescription database., Fujimoto M, Higuchi T, Hosomi K, Takada M, International journal of clinical pharmacology and therapeutics, 52, 9, 762, 769,   2014年09月, 査読有り
  • Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database., Takada M, Fujimoto M, Yamazaki K, Takamoto M, Hosomi K, Drug safety, 37, 6, 421, 431,   2014年06月, 査読有り
  • Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS., Fujimoto M, Hosomi K, Takada M, International journal of clinical pharmacology and therapeutics, 52, 4, 259, 266,   2014年04月, 査読有り
  • Difference in risk of gastrointestinal complications between users of enteric-coated and buffered low-dose aspirin., Takada M, Fujimoto M, Hosomi K, International journal of clinical pharmacology and therapeutics, 52, 3, 181, 191,   2014年03月, 査読有り
  • Difference between the frequencies of antisecretory drug prescriptions in users of buffered vs. enteric-coated low-dose aspirin therapies., Hachiken H, Murai A, Wada K, Kuwahara T, Hosomi K, Takada M, International journal of clinical pharmacology and therapeutics, 51, 10, 807, 815,   2013年10月, 査読有り
  • Evaluation of brilliance and visibility of fluorescence and chemiluminescence solution for training of preparing injections., Ishiwata S, Taga A, Sano H, Kobayashi M, Nomiyama J, Harada S, Kita A, Takada M, Sugiura R, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 131, 9, 1361, 1367,   2011年, 査読有り
  • Drug interaction between tacrolimus and carbamazepine in a Japanese heart transplant recipient: a case report., Wada K, Takada M, Sakai M, Ochi H, Kotake T, Okada H, Morishita H, Oda N, Mano A, Kato TS, Komamura K, Nakatani T, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 28, 4, 409, 411,   2009年04月, 査読有り
  • Limited sampling strategy for mycophenolic acid in Japanese heart transplant recipients: comparison of cyclosporin and tacrolimus treatment., Wada K, Takada M, Kotake T, Ochi H, Morishita H, Komamura K, Oda N, Mano A, Kato TS, Hanatani A, Nakatani T, Circulation journal : official journal of the Japanese Circulation Society, 71, 7, 1022, 1028,   2007年07月, 査読有り
  • Relationship between acute rejection and cyclosporine or mycophenolic acid levels in Japanese heart transplantation., Wada K, Takada M, Ueda T, Ochi H, Kotake T, Morishita H, Hanatani A, Nakatani T, Circulation journal : official journal of the Japanese Circulation Society, 71, 3, 289, 293,   2007年03月, 査読有り
  • Pharmacokinetic study and limited sampling strategy of cyclosporine in Japanese heart transplant recipients., Wada K, Takada M, Ueda T, Ochi H, Morishita H, Hanatani A, Nakatani T, Circulation journal : official journal of the Japanese Circulation Society, 70, 10, 1307, 1311,   2006年10月, 査読有り
  • Heart failure elevates serum levels of cibenzoline in arrhythmic patients., Kotake T, Takada M, Komamura K, Kamakura S, Miyatake K, Kitakaze M, Morishita H, Circulation journal : official journal of the Japanese Circulation Society, 70, 5, 588, 592,   2006年05月, 査読有り

MISC

  • 日米の有害事象自発報告データベースを用いた解析の比較と活用展望:―ニューキノロン系抗菌薬による有害事象の安全性シグナルを用いて―, 細見 光一, 新居 万莉, 藤本 麻依, 高田 充隆, 医薬品情報学, 17, 1, 15, 20,   2015年, 10.11256/jjdi.17.15, http://ci.nii.ac.jp/naid/130005084058
    概要:Objective: Signal detection by analyzing adverse event spontaneous report databases is used to monitor drug safety.  One of the major spontaneous report databases is the FDA Adverse Event Reporting System (FAERS).  Recently, the Japanese Adverse Drug Event Report database (JADER) was released.  To compare FAERS and JADER, we calculated the signals of adverse events by new quinolones (NQs).Methods: We extracted reports of adverse events by NQs from FAERS and JADER, and analyzed them using the ROR data mining algorithm.  Thirteen kinds of NQs were extracted, and the terms of adverse events extracted were defined by MedDRA.Results: There were 35,990,645 reports in FAERS and 1,643,404 reports in JADER.  Significant RORs were found for hypersensitivity (FAERS: 1.78, JADER: 1.47), arrhythmia (1.07, 0.68), hypoglycemia (1.80, 2.03), hyperglycemia (0.72, 0.78), rhabdomyolysis (1.01, 0.78), tendon disorders (15.18, 6.59), psychiatric symptoms (1.12, 0.45) and convulsion (0.99, 1.31).  We identified 4 types of adverse events by comparing FAERS and JADER: 1) Signal detection in both, 2) No signal detection in either, 3) Signal detection only in FAERS, 4) Signal detection only in JADER.Conclusion: Analyzing spontaneous report databases has several limitations, but is still a valuable tool for identifying potential associations between drugs and adverse events.  Spontaneous report databases may also be useful for detecting differences in adverse events between different races, countries and regions.
  • 分子標的抗がん剤によるB型肝炎,C型肝炎の解析:-日米の有害事象自発報告データベースを用いて-, 豕瀬 諒, 細見 光一, 朴 ピナウル, 藤本 麻依, 髙田 充隆, 医療薬学, 40, 5, 268, 277,   2014年, 10.5649/jjphcs.40.268, http://ci.nii.ac.jp/naid/130005068222
    概要:Several case reports of hepatitis B virus reactivation after rituximab administration have been documented. We investigated the association between hepatitis B and C and 15 kinds of molecular-targeted drugs for cancer. We compared two databases, the Food and Drug Administration Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report database (JADER) of the Pharmaceuticals and Medical Devices Agency (PMDA). Quantitative analysis involved calculating the reporting odds ratio (ROR) and 95% confidence interval (95% CI) as a measure of disproportionality. ROR is a tool that detects signals of adverse events for individual drugs, with signals detected when the lower limit of the 95% CI of ROR is > 1. We also investigated the timing of the adverse events and the age of the patients. There were 29,017,485 reports in FAERS and 2,079,653 reports in JADER. Signals were detected for rituximab-associated hepatitis B and hepatitis C, trastuzumab-associated hepatitis B, and imatinib-associated hepatitis B. In FAERS, hepatitis B often occurred within 1 month, whereas rituximab-associated hepatitis B often occurred 2-6 months after administration. In JADER, hepatitis B and rituximab-associated hepatitis B often occurred 1-3 months after administration. We conclude that signals of rituximab-associated hepatitis B and hepatitis C, trastuzumab-associated hepatitis B, and imatinib-associated hepatitis B are marked. Analyzing the timing and age of the patient at the occurrence of adverse events may suggest a relationship between drugs and these events.
  • 米国有害事象自発報告(FAERS)を用いたアスピリンおよび併用薬の消化管傷害に関する解析, 細見 光一, 藤本 麻依, 八軒 浩子, 炭床 啓太, 高田 充隆, 医薬品情報学, 15, 4, 147, 154,   2014年, 10.11256/jjdi.15.147, http://ci.nii.ac.jp/naid/130004941473
    概要:Objective: To examine the signal of gastrointestinal tract injury induced by aspirin and other drugs, we analyzed the US FDA Adverse Event Reporting System (FAERS).Methods: After deleting duplicate submissions, we analyzed the reports involving gastrointestinal tract injury associated with aspirin, H2-receptor antagonists (H2RAs), proton pump inhibitors (PPIs), ACE inhibitors, angiotensin II receptor blockers (ARBs), and antiplatelet and antithrombotic drugs.  The reporting odds ratio (ROR), a recognized pharmacovigilance tool, was used for the quantitative detection of signals.Results: Based on 29,017,485 co-occurrences, i.e., drug-adverse event pairs, found in 1,645,605 reports from 2004 to 2009, the ROR-associated gastrointestinal tract injury for aspirin alone, aspirin with H2RAs, aspirin with PPIs, aspirin with ACE inhibitors, aspirin with ARBs, and aspirin with antiplatelet and antithrombotic drugs were 2.88, 1.42, 1.46, 1.00, 1.05, and 2.98-8.26, respectively.  The following summarizes the types of listed reports: 86 reports described the daily aspirin doses, and 36/86 were between 75 and 100 mg; 343 reports described the periods between the start-date for aspirin and the date when gastrointestinal tract injury occurred, of which 128/343 were within one month while 215/343 were over one month; additionally, 78 reports described the total cumulative doses of aspirin, and 17/78 were between 1 and 5 g.Conclusion: The data suggest that H2RAs, PPIs, ACE inhibitors, and ARBs may reduce gastrointestinal tract injury associated with aspirin in possibility.
  • レセプトデータを用いたスタチン系薬剤による睡眠障害のリスクに 関する解析, 藤本 麻依, 高本 真志, 細見 光一, 高田 充隆, 医薬品情報学, 16, 2, 53, 62,   2014年, 10.11256/jjdi.16.53, http://ci.nii.ac.jp/naid/130004688313
    概要:Objective: To examine the association between statin use and the risk of sleep disturbances, data mining was performed on a claims database. Methods: Symmetry analysis was carried out to identify the risk of sleep disturbances after statin use during the period from January 2005 to December 2011.  Statin use in combination with hypnotic drugs was examined by prescription sequence symmetry analysis.  In this study, hypnotic drugs that are commonly prescribed for the treatment of insomnia were used as markers of sleep disturbances produced by statins. Likewise, event sequence symmetry analysis was undertaken to evaluate the association between statin use and the diagnosis of sleep disturbances.Results: Significant associations of statin use with short-acting hypnotic drugs were found, with an adjusted SR (sequence ratio) of 1.23 (95%CI: 1.04-1.45) at an interval of 12 months.  Otherwise, significant associations between individual statin use and hypnotic drug use were not found.  Significant associations between use of statins and the diagnosis of sleep disturbances were not also found in this study.Conclusions: Analysis of the claim database demonstrated that statin therapy might be associated with an emergence of sleep disturbances.  Therefore, individuals prescribed statins should be considered as having an increased risk of sleep disturbances.
  • 日-P1-045 実務実習事前学習における臨床薬学学習用電子教材活用の症例問題解決能力養成効果について(薬学教育(実務実習),ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来), 小竹 武, 野口 知世, 井上 知美, 高田 充隆, 掛樋 一晃, 野村 守弘, 山添 譲, 日本医療薬学会年会講演要旨集, 23,   2013年08月28日, http://ci.nii.ac.jp/naid/110009796908
  • 土-P2-201 重篤副作用疾患別対応マニュアルを補完する副作用情報の可視化と解析 : 日米の有害事象自発報告データベースを用いて(有害事象・副作用,一般演題 ポスター発表,再興、再考、創ろう最高の医療の未来), 細見 光一, 福田 亜矢, 藤本 麻依, 高田 充隆, 日本医療薬学会年会講演要旨集, 23,   2013年08月28日, http://ci.nii.ac.jp/naid/110009796458
  • ナショナルデータベースを用いた低用量アスピリン療法における消化管傷害リスクに関する研究, 髙田 充隆, 医療薬学, 39, 8, 471, 481,   2013年, 10.5649/jjphcs.39.471, http://ci.nii.ac.jp/naid/130004678964
    概要:To garner additional insights into the risk of gastrointestinal (GI) complications among users of low-dose aspirin (LDA) products, concomitant use of LDA products and anti-secretory drugs was investigated using the national database. The frequencies of gastrointestinal diseases among users of LDA products were also investigated. The main purpose of this study was to assess the differences in gastrointestinal damage risk between enteric-coated and buffered LDA product use.LDA use in combination with histamine H2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) was examined for the period January 2010 to December 2010. In addition, the frequencies of claim codes for gastrointestinal diseases among users of enteric-coated LDA and buffered LDA products were investigated for December 2010.In 2010, 24.0% of enteric-coated LDA users and 17.2% of buffered LDA users concomitantly used PPIs. There were substantial differences between enteric-coated LDA and buffered LDA users with regard to the frequency of PPI use. H2RAs were concomitantly used by 21.5% of enteric-coated LDA users and 20.8% of buffered LDA users. During December 2010, the frequencies of hemorrhagic gastric ulcer and lower gastrointestinal hemorrhage among entericcoated LDA users were higher than among buffered LDA users (0.31% vs 0.26%, and 0.085% vs 0.062%, respectively).These findings may imply that the risk of GI complications associated with buffered LDA use is lower than that with enteric-coated LDA use.
  • 6.データベース活用事例の紹介; アカデミアの立場から(1) ナショナルレセプトDB, 高田 充隆, 薬剤疫学, 17, 2, 155, 162,   2013年, 10.3820/jjpe.17.155, http://ci.nii.ac.jp/naid/130003372616
    概要:ここ数年の間,多くの健康保険請求が電子的に提出され,厚生労働省(MHLW)によりナショナルデータベース(NDB)に登録されている.NDB の医療サービスの質の向上における利用について評価する試行が始まった.筆者は,NDB を用いた医薬品使用状況研究を実施する機会を得たので,今回,MHLW による NDB 利用の手順を検討し,NDB の解析および薬剤疫学研究での活用における問題点について報告する.NDB は,他の医療データベースより大きく包括的であり,その知見は医薬品適正使用に関する貴重な情報の提供において,わが国の薬剤疫学研究に大きな影響を及ぼすと考えられる. (薬剤疫学 2012; 17(2): 155-162)
  • P1-603 薬剤師が参画する在宅医療に対する一般市民の意識(地域・在宅医療・薬薬連携,ポスター,一般演題,岐路に立つ医療〜千年紀の目覚め〜よみがえれ!ニッポン!薬の改革は我らが手で!), 堀野 智美, 大和 幹枝, 森 十久子, 鴨池 伸治, 佐伯 和彦, 岸田 充生, 高橋 直子, 北小路 学, 松野 純男, 高田 充隆, 日本医療薬学会年会講演要旨集, 22,   2012年10月10日, http://ci.nii.ac.jp/naid/110009618676
  • P1-427 有害事象自発報告データベースを用いた甲状腺機能異常事象の解析(医薬品情報・データベース,ポスター,一般演題,岐路に立つ医療〜千年紀の目覚め〜よみがえれ!ニッポン!薬の改革は我らが手で!), 細見 光一, 福田 亜矢, 高田 充隆, 日本医療薬学会年会講演要旨集, 22,   2012年10月10日, http://ci.nii.ac.jp/naid/110009618500
  • P1-653 大学における医療人養成のために薬学生が求められる能力とは?(薬学教育(その他),ポスター,一般演題,岐路に立つ医療〜千年紀の目覚め〜よみがえれ!ニッポン!薬の改革は我らが手で!), 小竹 武, 松本 優里香, 野口 知世, 井上 知美, 高田 充隆, 掛樋 一晃, 野村 守弘, 山添 譲, 日本医療薬学会年会講演要旨集, 22,   2012年10月10日, http://ci.nii.ac.jp/naid/110009618726
  • 静注用脂肪乳剤中の脂質ヒドロペルオキシド生成に関する経時的挙動, 北小路 学, 髙田 充隆, 医学と生物学, 156, 4, 168, 171,   2012年04月, http://ci.nii.ac.jp/naid/40019296766
  • チェーン薬局に所属する薬剤師の意識とジェネリック医薬品普及に関する調査研究, 長井 紀章, 大野 ひかる, 大和 幹枝, 堀野 智美, 北小路 学, 伊藤 吉將, 髙田 充隆, 医療薬学, 38, 2, 111, 117,   2012年, 10.5649/jjphcs.38.111, http://ci.nii.ac.jp/naid/130004502722
    概要:The penetration of low-priced generic drugs of good quality leads to not only a lower financial burden on patients, but also financial improvement of Japans medical insurance system. In this study, we investigated the relationship between the usage conditions of generic products (GE) and attitudes toward the reduction of national medical expense for pharmacists in chain community pharmacies in Japan using a questionnaire survey. The 20 - 25% usage conditions of GE were the highest in this study. The majority (89.2%) of pharmacists in the community pharmacy (positive group) have a positive attitude toward the reduction of national medical expense using GE, and the usage conditions of GE in the positive group are higher than that in the pharmacists that have a negative attitude toward the reduction of national medical expense using GE (negative group). In addition, the results of the questionnaire survey show that the pharmacists in the negative group still have doubts about the quality, effect and supply of GE in comparison with the positive group, and the pharmacists in the positive group were more interested in the generic drug dispensing fee in comparison with the negative group. In conclusion, the present study demonstrates that most pharmacists in this study have a positive attitude toward the reduction of national medical expense using GE, and the attitude toward GE in pharmacies relates to the usage conditions of GE. These findings provide significant information on the need for a reduction of national medical expense using GE.
  • 医療薬学研究のテキストマイニングによる計量的分析 —「医療薬学」と「日本病院薬剤師会雑誌」の比較, 八軒 浩子, 松岡 有紗, 村井 亜衣, 木下 佐昌子, 高田 充隆, 医薬品情報学, 13, 4, 152, 159,   2012年, 10.11256/jjdi.13.152, http://ci.nii.ac.jp/naid/130004551365
    概要:Objective: To quantitatively investigate the history of medical pharmacy research by pharmacists in Japan, original article titles from the Japanese Journal of Pharmaceutical Health Care and Sciences (Jpn J Pharm Health Care Sci) and the Journal of Japanese Society of Hospital Pharmacists (JJSHP) were analyzed by text-mining.Method: The titles of all original articles (2,611 and 2,260 articles) published in Jpn J Pharm Health Care Sci and JJSHP between 1975 and 2009 were collected from article databases and analyzed using KH Coder, the free software for quantitative text analysis of the Japanese language.  KH Coder extracts basic text information data by counting the occurrence rate of certain words.  Article titles were assigned to nine research categories according to coding rules, and the categorization results were analyzed quantitatively.Results: Between 1975 and 1989, "pharmaceutical investigation" was the major area of research in the Jpn J Pharm Health Care Sci.  Articles assigned to the category "drug therapy" gradually increased through the 1990s and, since 2000, "drug therapy" has dominated medical pharmacy research.  In the JJSHP between 1975 and 2004, no characteristic research area was found, and mainly research articles directly related to pharmacist practice were published.  However, from 2005 to 2009, articles assigned to the "drug therapy" category accounted for 34% of all published articles making "drug therapy" the major research area in the JJSHP.  Thus, in recent years, there is no obvious difference in research areas between the two journals.Conclusion: Our analyses suggest that drug therapy research is now at the center of medical pharmacy research by pharmacists in Japan.
  • 統合失調症意識調査と薬学部生・他学部生間の疾患認識の違い(一般演題(口頭)35,精神科領域(1),Enjoy Pharmacists' Lifestyles), 大和 幹枝, 阪口 寛子, 堀野 智美, 上垣 千波, 北小路 学, 松野 純男, 高田 充隆, 日本医療薬学会年会講演要旨集, 21,   2011年09月09日, http://ci.nii.ac.jp/naid/110008909424
  • P-0641 有害事象自発報告データベースを用いた医薬品併用による定量的シグナル指標の解析(一般演題 ポスター発表,薬剤疫学・医療経済,Enjoy Pharmacists' Lifestyles), 炭床 啓太, 細見 光一, 宮本 秀彰, 高田 充隆, 日本医療薬学会年会講演要旨集, 21,   2011年09月09日, http://ci.nii.ac.jp/naid/110008910107
  • P-0642 FDA有害事象自発報告データベースを用いた抗精神病薬による有害事象シグナルの解析(一般演題 ポスター発表,薬剤疫学・医療経済,Enjoy Pharmacists' Lifestyles), 朴 ピナウル, 細見 光一, 豕瀬 諒, 高田 充隆, 日本医療薬学会年会講演要旨集, 21,   2011年09月09日, http://ci.nii.ac.jp/naid/110008910108
  • P-0643 FDA有害事象自発報告データベースを用いた分子標的抗がん剤による肝炎関連有害事象シグナルの解析(一般演題 ポスター発表,薬剤疫学・医療経済,Enjoy Pharmacists' Lifestyles), 豕瀬 諒, 細見 光一, 朴 ピナウル, 高田 充隆, 日本医療薬学会年会講演要旨集, 21,   2011年09月09日, http://ci.nii.ac.jp/naid/110008910109
  • P-0798 ジェネリック医薬品普及と薬局薬剤師の意識に関する調査研究(一般演題 ポスター発表,後発医薬品,Enjoy Pharmacists' Lifestyles), 長井 紀章, 大野 ひかる, 大和 幹枝, 堀野 智美, 北小路 学, 伊藤 吉將, 松野 純男, 高田 充隆, 日本医療薬学会年会講演要旨集, 21,   2011年09月09日, http://ci.nii.ac.jp/naid/110008910263
  • P-0938 急性期および慢性期統合失調症患者を対象とした抗精神病薬の処方実態調査(一般演題 ポスター発表,精神科領域,Enjoy Pharmacists' Lifestyles), 北小路 学, 上垣 千波, 大和 幹枝, 阪口 寛子, 東 司, 高田 充隆, 日本医療薬学会年会講演要旨集, 21,   2011年09月09日, http://ci.nii.ac.jp/naid/110008910403
  • P-1137 在宅医療の周辺状況および薬剤師の在宅医療参画に対する市民の意識について : クラスター分析を主とした解析結果から(一般演題 ポスター発表,地域・在宅医療,Enjoy Pharmacists' Lifestyles), 堀野 智美, 大和 幹枝, 李 繭香, 佐伯 和彦, 鴨池 伸治, 森 十久子, 岸田 充生, 高橋 直子, 北小路 学, 松野 純男, 高田 充隆, 日本医療薬学会年会講演要旨集, 21,   2011年09月09日, http://ci.nii.ac.jp/naid/110008910602
  • P-1138 在宅医療へ薬剤師が参画するための問題解決策の探索及び提案(一般演題 ポスター発表,地域・在宅医療,Enjoy Pharmacists' Lifestyles), 李 繭香, 堀野 智美, 大和 幹枝, 山村 万里子, 高橋 直子, 北小路 学, 細見 光一, 岸田 充生, 近藤 直緒美, 菅濱 淳仁, 乾 英夫, 藤垣 哲彦, 松野 純男, 高田 充隆, 日本医療薬学会年会講演要旨集, 21,   2011年09月09日, http://ci.nii.ac.jp/naid/110008910603
  • P-1174 新教材を用いた抗がん剤調製トレーニング : 薬学実務実習事前学習における応用(一般演題 ポスター発表,薬学教育(実務実習),Enjoy Pharmacists' Lifestyles), 森 卯京, 石渡 俊二, 多賀 淳, 佐野 裕之, 小林 正隆, 原田 士朗, 小泉 祐一, 荒井 真美子, 藤原 琴, 亀本 浩司, 上田 和正, 大隅 奈奈, 池田 久雄, 稲井 恵子, 河内 昭人, 西山 辰美, 三上 正, 喜多 綾子, 高田 充隆, 杉浦 麗子, 日本医療薬学会年会講演要旨集, 21,   2011年09月09日, http://ci.nii.ac.jp/naid/110008910639
  • P-1230 調剤過誤シナリオを使用した模擬患者対応ロールプレイ実習 : アドバンスコミュニケーション学習(一般演題 ポスター発表,薬学教育(実務実習),Enjoy Pharmacists' Lifestyles), 小竹 武, 細見 光一, 大鳥 徹, 井上 知美, 安原 智久, 北小路 学, 船上 仁範, 谷野 公俊, 村上 悦子, 八軒 浩子, 高田 充隆, 松山 賢治, 日本医療薬学会年会講演要旨集, 21,   2011年09月09日, http://ci.nii.ac.jp/naid/110008910695
  • 運転行動が観測されたときの状況の通常からの逸脱の検出による交差点における右折行動の事故に至る可能性の予測, 林 紀典, 山田 啓一, 佐野 裕之, 小林 正隆, 野見山 淳, 原田 士郎, 喜多 綾子, 髙田 充隆, 杉浦 麗子, 電気学会論文誌. C, 電子・情報・システム部門誌 = The transactions of the Institute of Electrical Engineers of Japan. C, A publication of Electronics, Information and Systems Society, 131, 7, 1361, 1367,   2011年07月01日, 10.1541/ieejeiss.131.1361, http://ci.nii.ac.jp/naid/10030526954
    概要:  Personnel who prepare and administer chemotherapeutic agents have been reported to develop untoward effects. The use of appropriate techniques for preparing these agents is encouraged, and educational training systems that involve the use of a fluorescent or chemiluminescence reagent as placebos have been established to minimize potential exposure to these agents. However, the optimum conditions for the use and visibility of these placebos remain obscure. In this study, our results indicated that the fluorescence intensity of fluorescent reagent decreased when it was used at a concentration greater than 0.01%. Because drops created due to splashes and leaks are extremely small and easily evaporate, it is possible that the fluorescence resulting from such drops readily disappears despite using an anti-evaporation reagent. We also developed a method to evaluate the visibility of the small drop; using this method, we determined the distance at which the drop present on the pin could be seen by the observer. The distance at which the drop was clearly recognized as a pinpoint by using the fluorescence method was almost comparable to that for the chemiluminescence method. In the chemiluminescence method, the drop on the pin was faintly visible as a slightly bright area because of low background when observed at a certain distance that was much greater than that at which the drop was clearly visible; however, such an area was not observed in the fluorescence method. The results of our study will help in the selection of a training method depending on the situation.
  • 医療薬学研究の変遷に関する計量的分析, 後藤 佐昌子, 八軒 浩子, 高田 充隆, 医療薬学, 37, 1, 21, 30,   2011年, 10.5649/jjphcs.37.21, http://ci.nii.ac.jp/naid/130004502649
    概要:To quantitatively investigate the history of medical pharmacy research in Japan,we analyzed the titles of articles in theJapanese Journal of Pharmaceutical Health Care and Sciences and the Japanese Journal of Hospital Pharmacy,the principalmedical pharmacy journals in Japan,by text-mining.All article titles (2884 articles) between 1975 and 2009 were collectedfrom article databases,and the text of titles was analyzed using the KH Coder,free software for quantitative textanalysis of the Japanese language.This software produces basic information on text data such as the rate of occurrence ofcertain words.Nine research categories were identified through multivariate analysis of frequently appearing words.Also,coding rules were created to assign article titles to these research categories,and the categorization results were analyzed quantitatively.Pharmaceutical investigation was the principal category in the 1970 s and 80 s,with the quality evaluation of drugs asthe major area of research.Articles assigned to this category accounted for 41.4% of all articles published during the period1980-1984.Articles assigned to the drug therapy category began to gradually increase in the 1990 s,and since 2000,drugtherapy has been the major area of medical pharmacy research in Japan.In addition,there has been an increase in investigationsassociated with the education of pharmacists and pharmacy students in recent yearsOur findings suggest that there has been a shift in the dominant research area of medical pharmacy in Japan from qualityevaluation of drugs to patient care.
  • P1-100 FDA大規模有害事象自発報告(AERS)を用いた抗血小板薬の有害事象症例の解析(一般演題 ポスター発表,医薬品情報・データベース,臨床から学び臨床へと還元する医療薬学), 細見 光一, 炭床 啓太, 宮本 秀彰, 高田 充隆, 日本医療薬学会年会講演要旨集, 20,   2010年10月25日, http://ci.nii.ac.jp/naid/110008108480
  • 診療・治療ガイドライン 活用指南(第8回)虚血性心疾患, 高田 充隆, 月刊薬事, 51, 8, 1203, 1209,   2009年08月, http://ci.nii.ac.jp/naid/40016775562
  • 20-P3-469 ラット肝臓および小腸におけるCYP3AとP糖タンパク質の誘導に対するフェニトイン投与期間の影響(薬物動態(基礎),来るべき時代への道を拓く), 大鳥 徹, 岡 亜沙美, 川瀬 篤史, 高田 充隆, 岩城 正宏, 日本医療薬学会年会講演要旨集, 18,   2008年09月01日, http://ci.nii.ac.jp/naid/110006964412
  • 30P2-015 ロサルタンカリウムによる血清尿酸値に対する効果の検討(薬物療法(基礎と臨床),医療薬学の扉は開かれた), 関本 裕美, 小林 勝昭, 森下 秀樹, 中村 敏子, 河野 勇平, 高田 充隆, 日本医療薬学会年会講演要旨集, 16,   2006年09月01日, http://ci.nii.ac.jp/naid/110006961571
  • 小児におけるエポプロステノール(PGI_2)持続静注療法時の投与量の検討, 岡田 博, 高田 充隆, 森下 秀樹, 山田 修, 医療薬学, 32, 8, 805, 812,   2006年08月10日, 10.5649/jjphcs.32.805, http://ci.nii.ac.jp/naid/110004781846
    概要:The guideline on the dosing of Epoprostenol sodium (PGI_2) was established based on data for adults. In order to study the dosing regimen in children in Japan, we followed-up 7 patients under 16 years old with primary pulmonary hypertension (PPH) who received PGI_2 and analyzed their doses, hemodynamic parameters and brain natriuretic peptide (BNP) levels. The mean initial dose of PGI_2 was 2.0±0.7ng/kg/min and increases in the PGI_2 dosage occurred mostly within 2 weeks of the start of administration. Up to 28 days after starting administration, the mean interval between dose increases was 2.9±3.3 days and the mean dosage increase increment was 0.8±0.4ng/kg/min. Up to 3 months after starting administration, there was no statistically significant difference in doses between adults and children. Among severe adverse effects reported in acute dose-ranging in Japan, 7 of 18 cases were in children and the initial doses in 4 of them were over 2ng/kg/min. Based on these findings, appropriate dosing of PGI_2 in children is considered to be as follows: 1) The initial dose should be 0.5ng/kg/min, 2) The dosage increase interval should be over 2 days and the dosage increase increment between 0.5 and 1ng/kg/min, 3) Up to 3 months, the dose in children may be increased to the same extent as in adults.
  • 国立循環器病センターにおける心筋梗塞症に対する薬物療法についての処方実態調査 : 1996年3月と2004年3月の処方傾向の比較, 川戸 順之, 高田 充隆, 井上 知美, 橋詰 宏美, 野々木 宏, 森下 秀樹, 医療薬学, 32, 3, 242, 249,   2006年03月10日, 10.5649/jjphcs.32.242, http://ci.nii.ac.jp/naid/110004656732
    概要:In 1996, research was conducted at the National Cardiovascular Center to determine prescribing trends for drugs used in the treatment of myocardial infarction (MI). Since much evidence was collected and clinical guidelines for the treatment of MI were established, we thought that the prescribing trends might have changed in the following years so in 2004, we conducted research to determine what changes had occurred in the period from 1996 to 2004. The frequency of prescribing platelet aggregation inhibitors, β-adrenergic antagonists, angiotensin-converting-enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB) was higher in 2004, when platelet aggregation inhibitors were prescribed for 91.6% of the patients with MI, and aspirin was prescribed for 86.4% of the patients. The frequencies of prescribing multiple drugs for ischemic heart disease was high in both 1996 and 2004, and β-adrenergic antagonists had become the predominant drugs in multiple drug therapy in 2004. β_1-selective adrenergic antagonists without intrinsic sympathetic activity and αβ-adrenergic antagonists were major drugs among the β-adrenergic antagonists. Among calcium antagonists, the frequency of amlodipine use showed an upward trend in this eight-year period. In conclusion, our findings indicate that standard pharmacotherapy for MI based on the evidence and clinical guidelines has been introduced at NCVC.
  • 国立循環器病センターにおける心筋梗塞症に対する薬物療法についての処方実態調査‐1996年3月と2004年3月の処方傾向の比較‐:―1996年3月と2004年3月の処方傾向の比較―, 川戸 順之, 高田 充隆, 井上 知美, 橋詰 宏美, 野々木 宏, 森下 秀樹, 医療薬学, 32, 3, 242, 249,   2006年, 10.5649/jjphcs.32.242, http://ci.nii.ac.jp/naid/130004502215
    概要:In 1996, research was conducted at the National Cardiovascular Center to determine prescribing trends for drugs used in the treatment of myocardial infarction (MI). Since much evidence was collected and clinical guidelines for the treatment of MI were established, we thought that the prescribing trends might have changed in the following years so in 2004, we conducted research to determine what changes had occurred in the period from 1996 to 2004. The frequency of prescribing platelet aggregation inhibitors, β-adrenergic antagonists, angiotensin-converting-enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB) was higher in 2004, when platelet aggregation inhibitors were prescribed for 91.6% of the patients with MI, and aspirin was prescribed for 86.4% of the patients. The frequencies of prescribing multiple drugs for ischemic heart disease was high in both 1996 and 2004, and β-adrenergic antagonists had become the predominant drugs in multiple drug therapy in 2004. β1-selective adrenergic antagonists without intrinsic sympathetic activity and αβ-adrenergic antagonists were major drugs among the β-adrenergic antagonists. Among calcium antagonists, the frequency of amlodipine use showed an upward trend in this eight-year period. In conclusion, our findings indicate that standard pharmacotherapy for MI based on the evidence and clinical guidelines has been introduced at NCVC.
  • P-430 腎障害を伴う高血圧症患者に対する塩酸エホニジピンの有用性(1.薬物療法(基礎と臨床)5,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-), 中尾 元紀, 関本 裕美, 川戸 順之, 高田 充隆, 森下 秀樹, 日本医療薬学会年会講演要旨集, 15,   2005年09月01日, http://ci.nii.ac.jp/naid/110006960669
  • P-527 国立循環器病センターにおける心筋梗塞症に対する薬物療法についての処方実態調査 : 1996年と2004年を比較して(4.薬剤疫学・5.医薬品情報・データベース3,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-), 川戸 順之, 井上 知美, 橋詰 宏美, 高田 充隆, 森下 秀樹, 野々木 宏, 日本医療薬学会年会講演要旨集, 15,   2005年09月01日, http://ci.nii.ac.jp/naid/110006960766
  • P-617 Sirolimus溶出型冠動脈ステントに係る抗血小板療法の安全性の検討(8.有害事象・副作用(基礎と臨床)1,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-), 関本 裕美, 中尾 元紀, 川戸 順之, 和田 恭一, 老田 章, 高田 充隆, 森下 秀樹, 日本医療薬学会年会講演要旨集, 15,   2005年09月01日, http://ci.nii.ac.jp/naid/110006960856
  • 抗不整脈薬の適正使用の評価と推進に関する薬剤疫学的研究, 高田 充隆, 薬剤疫学, 10, 1, 29, 39,   2005年, 10.3820/jjpe1996.10.29, http://ci.nii.ac.jp/naid/130004345331
    概要:To evaluate and promote the rational use of antiarrhythmic drugs, a series of pharmacoepidemiological studies were performed. First, studies on hypoglycemia induced by cibenzoline were performed. The mechanism of the hypoglycemic effect of cibenzoline is related to an increase in insulin secretion. A significantly increased risk of hypoglycemia was observed in patients treated with cibenzoline in a case-controlled study. In particular, close attention should be paid to the occurrence of cibenzoline-induced hypoglycemia in elderly patients, those receiving high doses and in those with reduced renal function. After the introduction of TDM, the risk of hypoglycemia associated with cibenzoline use decreased together with an increase of the percentage of patients whose serum concentrations of cibenzoline had been measured. Dose adjustment based on TDM was beneficial for patients treated with cibenzoline in order to prevent hypoglycemia. In general, drugs are used in accordance with an approved dosage regimen in the expectation of an appropriate balance between efficacy and toxicity. However, a difference was seen between the approved dosage and the actual dose in cibenzoline therapy. Secondly, prescription research of several antiarrhythmic drugs was performed at five national hospitals. Antiarrhythmic drugs were used in lower doses than the approved dosage in clinical practice in Japan. Differences were seen between the approved dosage and the actual dose, and remarkable variations were seen in the dose distribution among the hospitals. The discrepancy between the approved dosage and practical dosage suggests that there is doubt as to whether the approved dosing regimens for antiarrhythmic drugs are appropriate.
  • 副作用収集に及ぼす影響因子と問題点 : 国立病院、ナショナルセンターに対する調査結果と国立循環器病センタ-における副作用収集状況の分析, 小竹 武, 高田 充隆, 橋本 博史, 和田 恭一, 柴川 雅彦, 医療薬学, 30, 10, 642, 650,   2004年10月10日, 10.5649/jjphcs.30.642, http://ci.nii.ac.jp/naid/110001166776
    概要:Up till now, the major drug information-related activity of hospital pharmacists has been to disseminate drug safety information issued by the Ministry of Health, Labour and Welfare. However, another important activity of pharmacists is noting adverse drug reactions (ADR) occurring in their own hospital and informing other medical staff about them. This information should also be reported to the Ministry of Health, Labour and Welfare so that the adverse reactions may be widely known among the medical community. In order to investigate the extent that pharmacists actually conduct such activities, a questionnaire survey was sent to 62 national hospitals and the number of ADR reports to the Ministry of Health, Labour and Welfare from 189 national hospitals in fiscal 2003 was investigated. The results indicated that most hospitals were insufficiently aware of the ADRs that occurred. A major reason for this was considered to be the lack of systems for collecting and reporting adverse reactions. Pharmacists were found to be involved in 78% of ADR reports. For the National Cardiovascular Center, the survey showed that the introduction of an ADR collecting system in which pharmacists played a leading role had significantly increased the number of ADR reports to the Ministry of Health, Labour and Welfare. Moreover, 37% of the reported ADRs were related to safety information from the Ministry of Health, Labour and Welfare. The survey results also suggested that providing safety information to physicians is effective in improving safety in the use of drugs. Although medical staff were only aware of about 3% of the ADRs, the crucial role of pharmacists in collecting and reporting ADRs was recognized.
  • P-182 心疾患患者におけるバンコマイシン体内動態の検討(10.TDM・投与設計,"薬剤師がつくる薬物治療"-薬・薬・学の連携-), 井倉 恵, 上野 和行, 光武 耕太郎, 島本 裕子, 福本 恭子, 高田 充隆, 森下 秀樹, 日本医療薬学会年会講演要旨集, 14,   2004年09月01日, http://ci.nii.ac.jp/naid/110006959648
  • P-183 心疾患を有する乳幼児・小児患児におけるテイコプラニン体内動態の解析(10.TDM・投与設計,"薬剤師がつくる薬物治療"-薬・薬・学の連携-), 島本 裕子, 井倉 恵, 上野 和行, 福本 恭子, 光武 耕太郎, 高田 充隆, 森下 秀樹, 日本医療薬学会年会講演要旨集, 14,   2004年09月01日, http://ci.nii.ac.jp/naid/110006959649
  • P-416 国立循環器病センターにおけるスタチン系薬剤の使用動向と実態に関する調査研究(3.薬剤疫学,"薬剤師がつくる薬物治療"-薬・薬・学の連携-), 奈須 史子, 和田 恭一, 高田 充隆, 森下 秀樹, 日本医療薬学会年会講演要旨集, 14,   2004年09月01日, http://ci.nii.ac.jp/naid/110006959882
  • P-417 循環器用薬のTDMによる投与量の適正化に関する研究(3.薬剤疫学,"薬剤師がつくる薬物治療"-薬・薬・学の連携-), 後藤 拓也, 齋藤 誠, 中井 正彦, 軍司 剛宏, 川戸 順之, 小竹 武, 高田 充隆, 柴川 雅彦, 日本医療薬学会年会講演要旨集, 14,   2004年09月01日, http://ci.nii.ac.jp/naid/110006959883
  • 国立循環器病センターにおける薬剤管理指導に関する調査 : パイロットスタディによる評価, 小竹 武, 志目田 由華, 田中 一彦, 高田 充隆, 柴川 雅彦, 医療薬学, 30, 3, 185, 190,   2004年03月10日, 10.5649/jjphcs.30.185, http://ci.nii.ac.jp/naid/110001166798
    概要:Conducting clinical pharmacy practice in consideration of inpatient needs is one of the most important activities of pharmacists. In view of this, we conducted a pilot study at the National Cardiovascular Center to evaluate the effectiveness of our practice of clinical pharmacy. During the study period, 892 drug compliance instructions were given to 312 patients and there were 1,785 events that had to be managed. In order to manage these events, we provided information in 2,007 instances to patients (65%) or medical staff (35%). Among the events, the frequency of adverse reactions was 6.3%, with a rate per drug compliance instruction of one in eight. Medical errors accounted for 1.9% of the events, giving a rate of one error per 24 drug compliance instructions. Twenty percent of all prescription changes arose from information provided by pharmacists and 6.0% of changes in prescriptions were attributable to the medication errors detected by pharmacists. Thus, pharmacists were involved in about 25% of prescription changes. As our conclusion, clinical pharmacy practice which helps to avoid adverse reactions and provides useful information to patients and medical staff is a prerequisite for effective pharmacotherapy.
  • 処方オーダリングシステムによる塩酸チクロピジンの適正使用の推進, 和田 恭一, 服部 雄司, 高田 充隆, 柴川 雅彦, 医療薬学, 30, 3, 211, 216,   2004年03月10日, 10.5649/jjphcs.30.211, http://ci.nii.ac.jp/naid/110001166802
    概要:Ticlopidine has been reported to cause critical adverse reactions, among them thrombotic thrombocytopenic purpura, granulocytopenia and liver failure. In view of this, emergency safety information has been issued on two occasions and after it was issued for the second time in July 2002, a warning function was incorporated into the computerized order entry system. Under this function, a warning message is displayed on the screen when this drug is to be prescribed for a patient for the first time and physicians can only enter a prescription order for ticlopidine when they have acknowledged the message. We compared the frequencies of prescribing ticlopidine and of conducting blood tests, and the rate of adverse reactions before and after the issue of the emergency safety information and introduction of the warning function. Patients treated with ticlopidine were selected from the prescription database file created from the prescription order entry system, which contains details of all the prescriptions filled for outpatients between January 1998 and December 2002. Following the issue of emergency safety information for the second time, the prescription frequency of ticlopidine started to decrease and there was a significant increase in the frequency of blood tests, though there had been no difference in the amount of blood testing between before and after the issue of emergency safety information for the first time. This showed that the timely provision of safety information to physicians through the computerized order entry system has been effective in promoting the proper use of ticlopidine.
  • 国立循環器病センターにおける薬剤管理指導に関する調査-パイロットスタディによる評価-:パイロットスタディによる評価, 小竹 武, 志目田 由華, 田中 一彦, 高田 充隆, 柴川 雅彦, 医療薬学, 30, 3, 185, 190,   2004年, 10.5649/jjphcs.30.185, http://ci.nii.ac.jp/naid/130004346602
    概要:Conducting clinical pharmacy practice in consideration of inpatient needs is one of the most important activities of pharmacists. In view of this, we conducted a pilot study at the National Cardiovascular Center to evaluate the effectiveness of our practice of clinical pharmacy. During the study period, 892 drug compliance instructions were given to 312 patients and there were 1, 785 events that had to be managed. In order to manage these events, we provided information in 2, 007 instances to patients (65 %) or medical staff (35%). Among the events, the frequency of adverse reactions was 6.3 %, with a rate per drug compliance instruction of one in eight. Medical errors accounted for 1.9% of the events, giving a rate of one error per 24 drug compliance instructions. Twenty percent of all prescription changes arose from information provided by pharmacists and 6.0 % of changes in prescriptions were attributable to the medication errors detected by pharmacists. Thus, pharmacists were involved in about 25 % of prescription changes. As our conclusion, clinical pharmacy practice which helps to avoid adverse reactions and provides useful information to patients and medical staff is a prerequisite for effective pharmacotherapy.
  • 処方オーダリングシステムによる塩酸チクロピジンの適正使用の推進, 和田 恭一, 服部 雄司, 高田 充隆, 柴川 雅彦, 医療薬学, 30, 3, 211, 216,   2004年, 10.5649/jjphcs.30.211, http://ci.nii.ac.jp/naid/130004346606
    概要:Ticlopidine has been reported to cause critical adverse reactions, among them thrombotic thrombocytopenic purpura, granulocytopenia and liver failure. In view of this, emergency safety information has been issued on two occasions and after it was issued for the second time in July 2002, a warning function was incorporated into the computerized order entry system. Under this function, a warning message is displayed on the screen when this drug is to be prescribed for a patient for the first time and physicians can only enter a prescription order for ticlopidine when they have acknowledged the message.
    We compared the frequencies of prescribing ticlopidine and of conducting blood tests, and the rate of adverse reactions before and after the issue of the emergency safety information and introduction of the warning function. Patients treated with ticlopidine were selected from the prescription database file created from the prescription order entry system, which contains details of all the prescriptions filled for outpatients between January 1998 and December 2002.
    Following the issue of emergency safety information for the second time, the prescription frequency of ticlopidine started to decrease and there was a significant increase in the frequency of blood tests, though there had been no difference in the amount of blood testing between before and after the issue of emergency safety information for the first time. This showed that the timely provision of safety information to physicians through the computerized order entry system has been effective in promoting the proper use of ticlopidine.
  • P-74 低用量アスピリン療法における抗潰瘍剤併用の実態に関する調査, 福本 恭子, 高田 充隆, 芝田 信人, 高田 寛治, 柴川 雅彦, 日本医療薬学会年会講演要旨集, 13,   2003年09月01日, http://ci.nii.ac.jp/naid/110004065005
  • P-79 処方オーダリングシステムによる塩酸チクロピジンの適正使用の推進, 服部 雄司, 和田 恭一, 高田 充隆, 柴川 雅彦, 日本医療薬学会年会講演要旨集, 13,   2003年09月01日, http://ci.nii.ac.jp/naid/110004065010
  • P-269 国立循環器病センターにおける薬剤管理指導に関する調査, 志目田 由華, 小竹 武, 高田 充隆, 田中 一彦, 柴川 雅彦, 日本医療薬学会年会講演要旨集, 13,   2003年09月01日, http://ci.nii.ac.jp/naid/110004065200
  • P-471 薬事法改正・臨床研究指針策定と医師主導型の治験・臨床研究 : JaSWAT-1 試験の経験をふまえて, 老田 章, 坂東 興, 上田 裕一, 村岡 勲, 木ノ下 智康, 森田 茂樹, 金谷 朗子, 末安 正典, 大北 裕, 大石 美恵, 藤岡 梨恵, 奥村 勝彦, 高田 充隆, 柴川 雅彦, 佐瀬 一洋, 日本医療薬学会年会講演要旨集, 13,   2003年09月01日, http://ci.nii.ac.jp/naid/110004065402
  • ワルファリンとフルボキサミン併用患者のカルテ調査による相互作用の検討, 和田 恭一, 保田 智恵子, 花房 小百合, 高田 充隆, 柴川 雅彦, 医療薬学, 28, 5, 468, 472,   2002年10月10日, 10.5649/jjphcs.28.468, http://ci.nii.ac.jp/naid/110001166633
    概要:Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is widely used in the treatment of. patients with depression. It is known that fluvoxamine inhibits the activity of human cytochrome P450 enzymes (CYP) responsible for the oxidative metabolism of many drugs. Inhibition of CYP results in a number of clinically important pharmacokinetic drug interactions. Therefore, the interaction between warfarin and fluvoxamine was evaluated. The patients treated with fluvoxamine were selected from the prescription database file made for the prescriptions order entry system, which contains all the prescriptions filled for the inpatients and outpatients. There were 106 patients treated with fluvoxamine between July 2000 and June 2001. Of 106 patients, 20 used warfarin concomitantly during the study period. Increased INR/Dose values were observed in all patients after the initiation of fluvoxamine therapy. Subsequently, the high INR/Dose values were observed during the concomitant use of warfarin and fluvoxamme (P<0.01). It is suggested that the increase in the anticoagulant activity of warfarin occurred when fluvoxamine is used concomitantly. Therefore, frequent coagulation tests are required in patients treated with warfarin after the initiation or discontinuation of fluvoxamine therapy. In conclusion, warfarin should be used with worry when fluvoxamine is used concomitantly.
  • 日本人におけるアロプリノール適正投与量の検討, 岡田 博, 老田 章, 上野 和行, 高田 充隆, 柴川 雅彦, 医療薬学, 28, 6, 564, 570,   2002年10月10日, 10.5649/jjphcs.28.564, http://ci.nii.ac.jp/naid/110001166645
    概要:Allopurinol is often used for the treatment of patients suffering from gout and hyperuricemia. However, adverse effects due to the accumulation of oxipunnol, the main active metabolite of allopurinol, have been reported in patients with renal insufficiency. Therefore, in order to prevent such adverse effects, some guidelines for the optimal dosage of allopurinol have been advocated. To evaluate these guidelines, the serum oxipurinol concentration in 101 patients with hyperuricemia treated with allopurinol was measured by HPLC. The serum oxipurinol concentration/dosage increased (p<0.01) as the creatinine clearance level decreased. In addition, to evaluate the optimum dosage based on the renal function, Ccr was classified into three groups (Ccr≦30mL/min 30mL/min
  • O-39 アミオダロンとジゴキシンの薬物相互作用における影響因子の評価, 秋好 健志, 上野 和行, 松山 賢治, 内田 亨弘, 高田 充隆, 柴川 雅彦, 日本医療薬学会年会講演要旨集, 12,   2002年09月24日, http://ci.nii.ac.jp/naid/110001265965
  • O-40 アミオダロンとカルベジロールの相互作用の検討, 今野 秀樹, 上野 和行, 加藤 隆児, 宮武 邦夫, 高田 充隆, 柴川 雅彦, 日本医療薬学会年会講演要旨集, 12,   2002年09月24日, http://ci.nii.ac.jp/naid/110001265966
  • O-42 ワルファリンの体内動態に及ぼすアミオダロンの影響, 桑原 史朗, 上野 和行, 宮武 邦夫, 高田 充隆, 柴川 雅彦, 日本医療薬学会年会講演要旨集, 12,   2002年09月24日, http://ci.nii.ac.jp/naid/110001265968
  • 不整脈に関する薬剤師の臨床活動, 橋本 博史, 高田 充隆, 柴川 雅彦, 心電図 = Electrocardiology, 22, 5,   2002年08月20日, http://ci.nii.ac.jp/naid/10012354080
  • 薬剤師からみた一般名処方と後発医薬品 (特集 適正な医療の提供における一般名処方と後発医薬品), 高田 充隆, 柴川 雅彦, 医療 = Japanese journal of National Medical Services : 国立医療学会誌, 56, 8, 465, 468,   2002年08月, 10.11261/iryo1946.56.465, http://ci.nii.ac.jp/naid/40019864098
  • HPLC法による血清中カルベジロール濃度簡易測定法とその臨床応用, 加藤 隆児, 上野 和行, 土下 喜正, 吉村 尋典, 高田 充隆, 駒村 和雄, 鎌倉 史郎, 宮武 邦夫, 柴川 雅彦, 医療薬学, 28, 1, 9, 15,   2002年02月10日, 10.5649/jjphcs.28.9, http://ci.nii.ac.jp/naid/110001166570
    概要:Carvedilol demonstrates α_1-, β_1-, β_2-receptor blocking activity and has recently been used for the treatment of heart failure. The serum concentrations of carvedilol were measured by high performance liquid chromatography (HPLC) using the method of Hokama et al. and Louis et al. with slight modifications. To extract carvedilol from the serum, we employed solid-phase extraction. The retention times of carvedilol and the internal standard were 7.1 and 5.8 minute, respectively. The detection limit was 0.25ng/mL. These results suggest that this assay is a rapid, simple and sensitive method. On the other hand, the mean±SD clearance of carvedilol was 1.10±0.541L/hr/kg and 0.611±0.320L/hr/kg in 4 male volunteers who received 10mg carvedilol orally and in 21 inpatients who received carvedilol b.i.d. for at least a week, respectively. Our findings indicated that even though the carvedilol concentrations increased depending on the dose, the individual variations among individuals were large.
  • ワルファリンとリファンピシン併用患者のカルテ調査による相互作用の検討, 和田 恭一, 小島 悦子, 高田 充隆, 柴川 雅彦, 医療薬学, 28, 1, 85, 90,   2002年02月10日, 10.5649/jjphcs.28.85, http://ci.nii.ac.jp/naid/110001166582
    概要:Rifampicin's ability to induce hepatic-microsomal enzymes is well known. As a result, rifampicin has often been implicated in drug interactions by reducing the effectiveness of many drugs that are metabolized by the hepatic-microsomal enzyme system. One such well known interaction is that of rifampicin and warfarin. The concomitant administration of rifampicin and warfarin results in the need for an unusually high maintenance dose of warfarin in order to obtain the desired therapeutic effect. The interaction between warfarin and rifampicin was investigated. The patients treated with rifampicin were selected from the prescription database file made for the prescriptions order entry system, and which contains all the prescriptions filled for the inpatients and outpatients. Thirty patients were treated with rifampicin between July 2000 and June 2001. Four of them used warfarin concomitantly during the study period. Decreased INR values were observed in all patients between 5 and 10 days after the initiation of rifampicin therapy. To maintain proper INR, rifampicin therapy resulted in the need for a two-to three-fold increase in the warfarin dosage. Subsequently, low INR/Dose values were observed during the concomitant use of warfarin and rifampicin (30%〜50%). A decrease in the anticoagulant activity of warfarin frequently occurs when rifampicin is used concomitantly. After the initiation and discontinuation of rifampicin therapy, frequent coagulation tests are required in patients treated with warfarmn. In conclusion, warfarin should be used with caution when rifampicin is used concomitantly.
  • ワルファリンとフルボキサミン併用患者のカルテ調査による相互作用の検討, 和田 恭一, 保田 智恵子, 花房 小百合, 高田 充隆, 柴川 雅彦, 医療薬学, 28, 5, 468, 472,   2002年, 10.5649/jjphcs.28.468, http://ci.nii.ac.jp/naid/130004346456
    概要:Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is widely used in the treatment of patients with depression. It is known that fluvoxamine inhibits the activity of human cytochrome P450 enzymes (CYP) responsible for the oxidative metabolism of many drugs. Inhibition of CYP results in a number of clinically important pharmacokinetic drug interactions.
    Therefore, the interaction between warfarin and fluvoxamine was evaluated. The patients treated with fluvoxamine were selected from the prescription database file made for the prescriptions order entry system, which contains all the prescriptions filled for the inpatients and outpatients. There were 106 patients treated with fluvoxamine between July 2000 and June 2001. Of 106 patients, 20 used warfarin concomitantly during the study period. Increased INR/Dose values were observed in all patients after the initiation of fluvoxamine therapy. Subsequently, the high INR/Dose values were observed during the concomitant use of warfarin and fluvoxamine (P<0.01). It is suggested that the increase in the anticoagulant activity of warfarin occurred when fluvoxamine is used concomitantly. Therefore, frequent coagulation tests are required in patients treated with warfarin after the initiation or discontinuation of fluvoxamine therapy. In conclusion, warfarin should be used with worry when fluvoxamine is used concomitantly.
  • HPLC法による血清中カルベジロール濃度簡易測定法とその臨床応用, 加藤 隆児, 上野 和行, 土下 喜正, 吉村 尋典, 高田 充隆, 駒村 和雄, 鎌倉 史郎, 宮武 邦夫, 柴川 雅彦, 医療薬学, 28, 1, 9, 15,   2002年, 10.5649/jjphcs.28.9, http://ci.nii.ac.jp/naid/130004346421
    概要:Carvedilol demonstrates α1-, β1-, β2- receptor blocking activity and has recently been used for the treatment of heart failure. The serum concentrations of carvedilol were measured by high performance liquid chromatography (HPLC) using the method of Hokama et al. and Louis et al. with slight modifications. To extract carvedilol from the serum, we employed solid-phase extraction. The retention times of carvedilol and the internal standard were 7.1 and 5.8 minute, respectively. The detection limit was 0.25ng/mL. These results suggest that this assay is a rapid, simple and sensitive method. On the other hand, the mean±SD clearance of carvedilol was 1.10 ±0.541L/hr/kg and 0.611±0.320L/hr/kg in 4 male volunteers who received 10mg carvedilol orally and in 21 inpatients who received carvedilol b.i.d. for at least a week, respectively. Our findings indicated that even though the carvedilol concentrations increased depending on the dose, the individual variations among individuals were large.
  • ワルファリンとリファンピシン併用患者のカルテ調査による相互作用の検討, 和田 恭一, 小島 悦子, 高田 充隆, 柴川 雅彦, 医療薬学, 28, 1, 85, 90,   2002年, 10.5649/jjphcs.28.85, http://ci.nii.ac.jp/naid/130004346432
    概要:Rifampicin's ability to induce hepatic-microsomal enzymes is well known. As a result, rifampicin has often been implicated in drug interactions by reducing the effectiveness of many drugs that are metabolized by the hepatic-microsomal enzyme system. One such well known interaction is that of rifampicin and warfarin. The concomitant administration of rifampicin and warfarin results in the need for an unusually high maintenance dose of warfarin in order to obtain the desired therapeutic effect.
    The interaction between warfarin and rifampicin was investigated. The patients treated with rifampicin were selected from the prescription database file made for the prescriptions order entry system, and which contains all the prescriptions filled for the inpatients and outpatients. Thirty patients were treated with rifampicin between July 2000 and June 2001. Four of them used warfarin concomitantly during the study period. Decreased INR values were observed in all patients between 5 and 10 days after the initiation of rifampicin therapy. To maintain proper INR, rifampicin therapy resulted in the need for a two-to three-fold increase in the warfarin dosage. Subsequently, low INR/Dose values were observed during the concomitant use of warfarin and rifampicin (30%-50%). A decrease in the anticoagulant activity of warfarin frequently occurs when rifampicin is used concomitantly. After the initiation and discontinuation of rifampicin therapy, frequent coagulation tests are required in patients treated with warfarin. In conclusion, warfarin should be used with caution when rifampicin is used concomitantly.
  • 適正な医療の提供における一般名処方と後発医薬品  薬剤師からみた一般名処方と後発医薬品, 高田 充隆, 柴川 雅彦, 医療, 56, 8, 465, 468,   2002年, 10.11261/iryo1946.56.465, http://ci.nii.ac.jp/naid/130004316126
    概要:一般名処方の導入と後発医薬品の有効利用は, 医療費の抑制における重要な施策である. 医師, 薬剤師および患者はそれぞれの立場で, 一般名処方の意義と後発医薬品の長所・短所について正しく理解する必要がある. また, 後発医薬品企業は安定供給の確保, 情報の収集・提供体制の整備, 製造管理・品質管理の徹底に努めなければならない. 後発医薬品の品質管理について, われわれ薬剤師が最も懸念することは, 先発医薬品と後発医薬品の生物学的同等性の問題である. 治療血中濃度域が狭いために, わずかな血中濃度の変化により副作用を生じたり, 効果が低下したりするような薬物で, 血中濃度モニタリングの対象となっている薬物についてはとくに注意が必要である.一般名処方における薬剤の選択に関する薬剤師の責任は重く, 患者の経済的負担の側面と薬剤学的な妥当性から適正な薬剤が選択されなければならない.
  • P-72 グリベンクラミドとグリクラジドにおける低血糖リスクの比較, 寺澤 美智代, 高田 充隆, 柴川 雅彦, 日本医療薬学会年会講演要旨集, 11,   2001年09月01日, http://ci.nii.ac.jp/naid/110002336867
  • 輸血管理ネットワークシステムの運用評価 : 輸血用血液製剤の適正使用の推進をめざしたヒューマンインターフェイスの改善, 高田 雅弘, 岩谷 泰之, 河合 健, 山本 賢, 宮田 茂樹, 千葉 喜英, 中沢 一雄, 高田 充隆, 柴川 雅彦, 医療情報学連合大会論文集, 20, 176, 177,   2000年11月23日, http://ci.nii.ac.jp/naid/10010610646
  • O-12 ワルファリンの薬物動態に及ぼすアミオダロンの影響, 松元 加奈, 上野 和行, 森井 恵, 橋本 博史, 高田 充隆, 柴川 雅彦, 日本病院薬学会年会講演要旨集, 10,   2000年09月01日, http://ci.nii.ac.jp/naid/110001788343
  • O-13 鉄イオンによるミコフェノール酸モフェチルの吸収阻害, 森井 恵, 上野 和行, 小川 昭彦, 加藤 隆児, 吉村 尋典, 和田 恭一, 橋本 博史, 高田 充隆, 中谷 武嗣, 柴川 雅彦, 日本病院薬学会年会講演要旨集, 10,   2000年09月01日, http://ci.nii.ac.jp/naid/110001788344
  • O-100 外来患者の服薬コンプライアンスに及ぼす TDM の影響, 小田 あゆみ, 上野 和行, 松元 加奈, 高田 充隆, 柴川 雅彦, 日本病院薬学会年会講演要旨集, 10,   2000年09月01日, http://ci.nii.ac.jp/naid/110001788430
  • P-280 高血圧教室参加患者の退院後追跡調査, 齋藤 綾子, 小俣 智世, 井上 知美, 田中 秀子, 橋詰 宏美, 赤井 裕子, 加藤 亜紀, 橋本 博, 高田 充隆, 柴川 雅彦, 河野 雄平, 瀧下 修一, 日本病院薬学会年会講演要旨集, 10,   2000年09月01日, http://ci.nii.ac.jp/naid/110001788751
  • 薬剤管理指導業務における症例報告 その3 : 人工透析患者において薬物血中濃度モニタリングによりピルジカイニドおよびジゴキシンの適正投与量を設定し得た一例, 森井 恵, 上野 和行, 松元 加奈, 高田 充隆, 野嶋 祐兵, 坂巻 文雄, 中西 宣文, 柴川 雅彦, 病院薬学, 26, 4, 398, 402,   2000年08月10日, 10.5649/jjphcs1975.26.398, http://ci.nii.ac.jp/naid/110001166995
    概要:A 67-year-old man who had been receiving hemodialysis (HD) was administered pilsicainide and digoxin for the treatment of paroxysmal atrial fibrillation. Thereafter, when undergoing HD, ventricular fibrillation and flutter frequently appeared, and he was therefore admitted to National Cardiovascular Center. After being admitted, the administration of pilsicainide and digoxin was immediately stopped due to a widening QRS on ECG. After that the terminal half-time (t_<1/2>) of pilsicainide and digoxin were calculated and these drugs were restarted base on his calculated t_<1/2>. Subsequently a good control of arrhythmia without any side effects was obtained at this dosage. The above findings suggested that although the dose of digoxin in this case ranged from one-sixth to one-third of the normal dose when the renal function was normal, the dose of pilsicainide was only about one-tenth that of a normal dose, and a remarkable difference was observed between the dose of digoxin and pilsicainide. This case suggests that drugs, which are mainly eliminated in the kidney, especially pilsicainide, should thus be carefully monitored regarding their influence on the renal function in HD patients, since such therapy could lead to renal function failure.
  • シロスタゾールの薬物動態に影響を及ぼす因子の検討および血小板凝集能を用いた薬物動態 : 薬効動態解析, 石田 茂伸, 森井 恵, 上野 和行, 高田 充隆, 阪田 敏幸, 岡本 章, 小林 順二郎, 門田 治, 小泉 信達, 笹子 佳門, 柴川 雅彦, 病院薬学, 26, 3, 264, 272,   2000年06月10日, 10.5649/jjphcs1975.26.264, http://ci.nii.ac.jp/naid/110001166977
    概要:Cilostazol is being developed for the treatment of intermittent claudication due to peripheral arterial disease (PAD). In this study, we measured the serum cilostazol concentrations and plate-let aggregations induced by adenosine diphosphate (ADP) and collagen, and also investigated the pharmacokinetics and pharmacodynamics of cilostazol in inpatients receiving cilostazol therapy. No significant difference was observed in C/D (serum trough concentration/dose) between males and females. A trend toward increasing the serum cilostazol concentration by increasing the dose (mg/kg) was observed (P<0.05). The interindividual variation of the C/D for cilostazol was found to be very large. No significant difference was observed between the C/D for cilostazol and the age. GPT or Ccr. A statistical correlation was observed between the serum cilostazol concentration and the maximum extent of aggregation (%) induced by ADP and collagen (P<0.05).
  • シベンゾリン投与患者における血清中シベンゾリン濃度と空腹時血糖値の関係, 上野 和行, 森井 恵, 石田 茂伸, 玉村 晃, 松元 加奈, 小田 あゆみ, 高田 充隆, 鎌倉 史郎, 柴川 雅彦, 病院薬学, 26, 3, 304, 308,   2000年06月10日, 10.5649/jjphcs1975.26.304, http://ci.nii.ac.jp/naid/110001166982
    概要:The relationship between the serum trough concentrations of cibenzoline and the fasting blood glucose (FBG) levels were evaluated in 78 inpatients received cibenzoline therapy. As a result, as the serum trough concentrations of cibenzoline increased, the FBG levels decreased in inverse proportion. The FBG levels after the administration of cibenzoline decreased significantly (P<0.01) more than before administration. In addition, when the serum cibenzoline concentrations were higher the FBG levels also decreased significantly (P<0.01) more than when the serum concentrations were lower. The mean serum concentration when the FBG levels were less than 80 mg/dL was higher than that when the FBG levels were lover 90 mg/dL (383±273 vs 284±189 ng/mL, P<0.071). These results suggest that more careful monitoring of the side effects of cibenzoline caused by a decrease in the FBG is thus needed in patients receiving cibenzoline therapy.
  • テイコプラニン主要構成6成分のロット間における組成比変動, 松元 加奈, 上野 和行, 高田 充隆, 柴川 雅彦, 病院薬学, 26, 3, 345, 348,   2000年06月10日, 10.5649/jjphcs1975.26.345, http://ci.nii.ac.jp/naid/110001166989
    概要:Objectives : Teicoplanin is an antibiotic complex consisting of five closely related components of similar polarity designated A2-1, 2, 3, 4 and 5 and a more polar factor A 3. The variations in the constitution ratio of the six major components were measured to evaluate the validation of teicoplanin preparations. Methods : The concentrations of each component of teicoplanin were measured in 14 lots by high performance liquid chromatography. Results : No significant differences were observed regarding the variation in the constitution ratio between the A 2 and A 3 groups. However, significant differences were found in the A 2-1 component . Conclusions : Variations of the constitution ratio in Teicoplanin preparations may possibly affect the pharmacokinetics of teicoplanin. More care is thus called for during the manufacturing process.
  • 服薬指導における症例報告 その2 : ピルメノールにより肝障害を引き起こしたと疑われた一症例およびその検討, 森井 恵, 上野 和行, 高田 充隆, 日野 裕, 笹子 佳門, 柴川 雅彦, 病院薬学, 26, 2, 183, 187,   2000年04月10日, 10.5649/jjphcs1975.26.183, http://ci.nii.ac.jp/naid/110001166966
    概要:A 56-year-old woman inpatient that had been administrated warfarin, digoxin, verapamil and disopyramide after undergoing surgery for a mitral and aortic valve replacement associated with artrial fibrillation received a 300 mg daily dose of disopyramide therapy before and after the operation. Although the serum disopyramide concentration was within the normal therapeutic range, dry mouth appeared as a side effect. Disopyramide was thus changed to pirmenol. The trough level of pirmenol was 2.1 μg/mL at seven days after starting pirmenol therapy at the dose of 300 mg/day, and the dose was there after decreased to 200 mg/day. About two weeks after pirmenol therapy was started. liver injury was observed. At approximately 30 days after pirmenol aciministration was stopped, the liver function returned to a normal level. On the other hand. according to recent reports pirmenol was suggested to show a high level in the liver. The reported levels of pirmenol were also similar to for amiodarone and aprindine. which are both well known to induce side effect in the liver. Therefore, one of the reasons that pimenol induced liver injury may be due to its high levels in the liver.
  • 臓器移植チームにおける薬剤師の役割, 高田 充隆, 柴川 雅彦, ファルマシア, 36, 4, 293, 297,   2000年04月01日, http://ci.nii.ac.jp/naid/110003660589
  • 当〔国立循環器病〕センター第1例目の心臓移植後患者の薬剤管理指導報告--腎機能変化に伴う薬物相互作用を含む, 森井 恵, 上野 和行, 高田 充隆, 月刊薬事, 42, 2, 303, 309,   2000年02月, http://ci.nii.ac.jp/naid/40001041918
  • シロスタゾールの薬物動態に影響を及ぼす因子の検討および血小板凝集能を用いた薬物動態  薬効動態解析, 石田 茂伸, 森井 恵, 上野 和行, 高田 充隆, 阪田 敏幸, 岡本 章, 小林 順二郎, 門田 治, 小泉 信達, 笹子 佳門, 柴川 雅彦, 病院薬学, 26, 3, 264, 272,   2000年, 10.5649/jjphcs1975.26.264, http://ci.nii.ac.jp/naid/130004299771
    概要:Cilostazol is being developed for the treatment of intermittent claudication due to peripheral arterial disease (PAD). In this study, we measured the serum cilostazol concentrations and platelet aggregations induced by adenosine diphosphate (ADP) and collagen, and also investigated the pharmacokinetics and pharmacodynamics of cilostazol in inpatients receiving cilostazol therapy. No significant difference was observed in C/D (serum trough concentration/dose) between males and females. A trend toward increasing the serum cilostazol concentration by increasing the dose (mg/kg) was observed (P<0.05). The interindividual variation of the C/D for cilostazol was found to be very large. No significant difference was observed between the C/D for cilostazol and the age, GPT or Ccr. A statistical correlation was observed between the serum cilostazol concentration and the maximum extent of aggregation (%) induced by ADP and collagen (P<0.05).
  • シベンジリン投与患者における血清中シベンジリン濃度と空腹時血糖値の関係, 上野 和行, 森井 恵, 石田 茂伸, 玉村 晃, 松元 加奈, 小田 あゆみ, 高田 充隆, 鎌倉 史郎, 柴川 雅彦, 病院薬学, 26, 3, 304, 308,   2000年, 10.5649/jjphcs1975.26.304, http://ci.nii.ac.jp/naid/130004299776
    概要:The relationship between the serum trough concentrations of cibenzoline and the fasting blood glucose (FBG) levels were evaluated in 78 inpatients received cibenzoline therapy. As a result, as the serum trough concentrations of cibenzoline increased, the FBG levels decreased in inverse proportion. The FBG levels after the administration of cibenzoline decreased significantly (P<0.01) more than before administration. In addition, when the serum cibenzoline concentrations were higher the FBG levels also decreased significantly (P<0.01) more than when the serum concentrations were lower. The mean serum concentration when the FBG levels were less than 80mg/dL was higher than that when the FBG levels were lover 90mg/dL (383±273 vs 284±189ng/mL, P<0.071). These results suggest that more careful monitoring of the side effects of cibenzoline caused by a decrease in the FBG is thus needed in patients receiving cibenzoline therapy.
  • テイコプラニン主要構成6成分のロット間における組成比変動, 松元 加奈, 上野 和行, 高田 充隆, 柴川 雅彦, 病院薬学, 26, 3, 345, 348,   2000年, 10.5649/jjphcs1975.26.345, http://ci.nii.ac.jp/naid/130004299783
    概要:Objectives: Teicoplanin is an antibiotic complex consisting of five closely related components of similar polarity designated A2-1, 2, 3, 4 and 5 and a more polar factor A 3. The variations in the constitution ratio of the six major components were measured to evaluate the validation of teicoplanin preparations.
    Methods: The concentrations of each component of teicoplanin were measured in 14 lots by high performance liquid chromatography.
    Results: No significant differences were observed regarding the variation in the constitution ratio between the A 2 and A 3 groups. However, significant differences were found in the A 2-1 component.
    Conclusions: Variations of the constitution ratio in Teicoplanin preparations may possibly affect the pharmacokinetics of teicoplanin. More care is thus called for during the manufacturing process.
  • 服薬指導における症例報告 その2  ピルメノールにより肝障害を引き起こしたと疑われた一症例およびその検討, 森井 恵, 上野 和行, 高田 充隆, 日野 裕, 笹子 佳門, 柴川 雅彦, 病院薬学, 26, 2, 183, 187,   2000年, 10.5649/jjphcs1975.26.183, http://ci.nii.ac.jp/naid/130004299760
    概要:A 56-year-old woman inpatient that had been administrated warfarin, digoxin, verapamil and disopyramide after undergoing surgery for a mitral and aortic valve replacement associated with artrial fibrillation received a 300mg daily dose of disopyramide therapy before and after the operation. Although the serum disopyramide concentration was within the normal therapeutic range, dry mouth appeared as a side effect. Disopyramide was thus changed to pirmenol. The trough level of pirmenol was 2.1μg/mL at seven days after starting pirmenol therapy at the dose of 300 mg/day, and the dose was there after decreased to 200mg/day. About two weeks after pirmenol therapy was started, liver injury was observed. At approximately 30 days after pirmenol administration was stopped, the liver function returned to a normal level.
    On the other hand, according to recent reports pirmenol was suggested to show a high level in the liver. The reported levels of pirmenol were also similar to for amiodarone and aprindine, which are both well known to induce side effect in the liver. Therefore, one of the reasons that pimenol induced liver injury may be due to its high levels in the liver.
  • 薬剤管理指導業務における症例報告 その3  人工透析患者において薬物血中濃度モニタリングによるピルジカイニドおよびジゴキシンの適正投与量を設定し得た一例:人工透析患者において薬物血中濃度モニタリングによりピルジカイニドおよびジゴキシンの適正投与量を設定し得た一例, 森井 恵, 上野 和行, 松元 加奈, 高田 充隆, 野嶋 祐兵, 坂巻 文雄, 中西 宣文, 柴川 雅彦, 病院薬学, 26, 4, 398, 402,   2000年, 10.5649/jjphcs1975.26.398, http://ci.nii.ac.jp/naid/130004103223
    概要:A 67-year-old man who had been receiving hemodialysis (HD) was administered pilsicainide and digoxin for the treatment of paroxysmal atrial fibrillation. Thereafter, when undergoing HD, ventricular fibrillation and flutter frequently appeared, and he was therefore admitted to National Cardiovascular Center. After being admitted, the administration of pilsicainide and digoxin was immediately stopped due to a widening QRS on ECG. After that the terminal half-time (t1/2) of pilsicainide and digoxin were calculated and these drugs were restarted base on his calculated t1/2. Subsequently a good control of arrhythmia without any side effects was obtained at this dosage.
    The above findings suggested that although the dose of digoxin in this case ranged from onesixth to one-third of the normal dose when the renal function was normal, the dose of pilsicainide was only about one-tenth that of a normal dose, and a remarkable difference was observed between the dose of digoxin and pilsicainide.
    This case suggests that drugs, which are mainly eliminated in the kidney, especially pilsicainide, should thus be carefully monitored regarding their influence on the renal function in HD patients, since such therapy could lead to renal function failure.
  • シベンゾリンの蛋白結合に及ぼすアルブミンおよびα_1酸性糖蛋白質の影響, 上野 和行, 森井 恵, 西岡 純子, 吉村 尋典, 辻 美里, 平木 精一, 高田 充隆, 柴川 雅彦, 病院薬学, 25, 6, 643, 648,   1999年12月10日, 10.5649/jjphcs1975.25.643, http://ci.nii.ac.jp/naid/110001166931
    概要:The effect of albumin and α_1 acid-glycoprotein (AAG) on the binding of cibenzoline was studied using the pH 7.4 phosphate buffer (PBs) and human plasma. The binding in 40 inpatients who received cibenzoline therapy was measured. The cibenzoline concentrations of samples were measured by high performance liquid chromatography. As a result, not only the PBS but also human plasma samples the binding increased in propotion as the concentrations of albumin and AAG increased. On the other hard the binding decreased in inverse proportion as the total cibenzoline concentration increased. However, in the patient samples the effect of the total concentration of cibenzoline and the concentrations of albumin and AAG on the binding was slight and the mean binding ratio was about 80%. These results suggest that when clinically monitoring the cibenzoline blood concentration in clinical monitoring the total concentrations of cibenzoline alone appears to be sufficient.
  • 循環器専門病院薬剤部に求められる機能と職能 (月刊薬事40周年記念特大号 病院薬剤師--21世紀への挑戦--新たな職能への取り組み) -- (病院薬剤師の機能と職能), 高田 充隆, 柴川 雅彦, 月刊薬事, 41, 12, 2527, 2529,   1999年11月, http://ci.nii.ac.jp/naid/40001041825
  • 経皮吸収型虚血性心疾患治療薬3製剤間における副作用としての皮膚刺激性の臨床および基礎的検討, 森井 恵, 上野 和行, 赤井 裕子, 辻 美里, 高田 雅弘, 高田 充隆, 柴川 雅彦, 病院薬学, 25, 5, 495, 501,   1999年10月10日, 10.5649/jjphcs1975.25.495, http://ci.nii.ac.jp/naid/110001166911
    概要:The side effects of nitrate patch preparations for ischemic heart disease were evaluated in both inpatients and volunteers. Therefore, a removal test of hony cells. adhesion test and down rolling ball (tack) test were all studied to clarify the pharmaceutical characteristics of these preparations. As a result. the score of the skin irritation of the NitrodermTTS^<[O!R]> preparation was significantly higher than that for the other two preparations (Antup^<[O!R]> and Frandol tape S^<[O!R]> preparation). No correlations were observed between skin irritation and the amount of homy cells removed by the NitrodermTTS^<[O!R]>. The Antupn^<[O!R]> preparation was the strongest for the adhesion test. How-ever. the NitrodermTTS^<[O!R]>) preparation was the strongest for the tack test. These findings suggest that one reason for the increased skin irritation of NitrodermTTS^<[O!R]> may be due to its high degree tack influence.
  • 25-04-14 シロスタゾールの薬物動態及び薬効動態に関する研究, 石田 茂伸, 森井 恵, 上野 和行, 高田 充隆, 阪田 敏幸, 岡本 章, 小林 順二郎, 門田 治, 小泉 信達, 笹子 佳門, 柴川 雅彦, 日本病院薬学会年会講演要旨集, 9,   1999年08月20日, http://ci.nii.ac.jp/naid/110001265530
  • 25-04-21 メキシレチンの薬物動態及び尿中代謝物の解析, 玉村 晃, 上野 和行, 高田 充隆, 柴川 雅彦, 日本病院薬学会年会講演要旨集, 9,   1999年08月20日, http://ci.nii.ac.jp/naid/110001265537
  • 25-A6-27 ピルメノールにより肝障害を引き起こしたと疑われた一症例およびその検討, 森井 恵, 上野 和行, 高田 充隆, 日野 裕, 笹子 佳門, 柴川 雅彦, 日本病院薬学会年会講演要旨集, 9,   1999年08月20日, http://ci.nii.ac.jp/naid/110001265615
  • 26-P7-52 FPIA 法による血中テイコプラニン濃度測定の精度評価とその臨床応用, 辻 美里, 平木 精一, 上野 和行, 高田 充隆, 柴川 雅彦, 日本病院薬学会年会講演要旨集, 9,   1999年08月20日, http://ci.nii.ac.jp/naid/110001265864
  • 26-P7-62 「心筋梗塞症」患者への薬物療法の変遷 : 診療ガイドライン発表前後における薬物療法の検討, 廣畑 和弘, 永井 聡子, 加藤 亜紀, 高田 充隆, 野々木 宏, 柴川 雅彦, 日本病院薬学会年会講演要旨集, 9,   1999年08月20日, http://ci.nii.ac.jp/naid/110001265874
  • アミオダロンおよびデスエチルアミオダロンの簡易測定法ならびにその臨床応用, 玉置 耕一, 上野 和行, 辻 美里, 平木 精一, 高田 充隆, 鎌倉 史郎, 柴川 雅彦, 病院薬学, 25, 1, 28, 33,   1999年02月10日, 10.5649/jjphcs1975.25.28, http://ci.nii.ac.jp/naid/110001166852
    概要:A simple reverse-phase high-performance liquid chromatographic (HPLC) assay for the measurement of amiodarone and its metabolite, desethylamiodarone in the serum was established. The ODS-2 column was used and the absorbance of the effluent from the column at 254 nm was measured. The standard curves for amiodarone and desethylamiodarone were linear up to 5μg/ml. The coefficent of variation (CV) was within 10% at a concentration of 100 ng/ml, and the CV of the intra-and interday variation was within 10% at concentrations of 0.25. 0.5 and I μg/ ml, respectively. These results suggest that the limit of detection is 100 ng/ml for amiodarone and desethylamiodarone, and this assay is thus considered to be a reliable method in clinical practice. On the other hand, the serum amiodarone and desethylamiodarone concentrations were measured in 10 inpatients who received amiodarone for at least 1 month. No significant correlation was observed between the doses and serum drug concentrations. There findings therefore suggest that TDM(Therapeutic Drug Monitoring) should be performed on anyone taking amiodarone.
  • ワルファリンによると考えられる薬剤性肝機能障害の一例, 橋本 博史, 上野 和行, 平木 精一, 高田 充隆, 松尾 汎, 柴川 雅彦, 病院薬学, 25, 1, 60, 64,   1999年02月10日, 10.5649/jjphcs1975.25.60, http://ci.nii.ac.jp/naid/110001166857
    概要:A 61-year-old woman weighting 57.9 kg was hospitalized with deep vein thrombosis. She received warfarin therapy. At first 2 mg/day of warfarin was administered for five days while from the 6 th day the dose was increased to 3 mg/day. From the 8 th day the dose was increased to 4 mg/day. Although the GOT and GPT value was within the normal range before the warfarin therapy was started, on the 5 th day after the therapy was started the GOT and GPT Ievels were 68 and 61 Iu/1, respectively, while on the 12 th day the GOT and GPT had increased even more (99 and 212). We consider such hepatic evidence to be due to the administration of warfarin and its administration was thus stopped. On the 4 th day after warfarin was stopped the GOT and GPT Ievels decreased to 55 and 128, respectively, and after that it decreased even more. Both the GOT and GPT decreased to the normal range wlthin one month. On the other hand, in order to evaluate an allergy to warfarin, a patch test of warfarin was examined, however, the results of the test was negative. No reports of hepatic failure due to the administration of warfarin could be found on Midline from 1966 to February 1998. These results suggest this case to be a very rare one, however, further study is called for in the future.
  • シベンジリンの蛋白結合に及ぼすアルブミンおよびα1酸性糖蛋白質の影響, 上野 和行, 森井 恵, 西岡 純子, 吉村 尋典, 辻 美里, 平木 精一, 高田 充隆, 柴川 雅彦, 病院薬学, 25, 6, 643, 648,   1999年, 10.5649/jjphcs1975.25.643, http://ci.nii.ac.jp/naid/130004299742
    概要:The effect of albumin and α1 acid-glycoprotein (AAG) on the binding of cibenzoline was studied using the pH 7.4 phosphate buffer (PBs) and human plasma. The binding in 40 inpatients who received cibenzoline therapy was measured. The cibenzoline concentrations of samples were measured by high performance liquid chromatography. As a result, not only the PBs but also human plasma samples the binding increased in propotion as the concentrations of albumin and AAG increased. On the other hard the binding decreased in inverse proportion as the total cibenzoline concentration increased. However, in the patient samples the effect of the total concentration of cibenzoline and the concentrations of albumin and AAG on the binding was slight and the mean binding ratio was about 80%. These results suggest that when clinically monitoring the cibenzoline blood concentration in clinical monitoring the total concentrations of cibenzoline alone appears to be sufficient.
  • 経皮吸収型虚血性心疾患治療薬3製剤間における副作用としての皮膚刺激性の臨床および基礎的検討, 森井 恵, 上野 和行, 赤井 裕子, 辻 美里, 高田 雅弘, 高田 充隆, 柴川 雅彦, 病院薬学, 25, 5, 495, 501,   1999年, 10.5649/jjphcs1975.25.495, http://ci.nii.ac.jp/naid/130004299722
    概要:The side effects of nitrate patch preparations for ischemic heart disease were evaluated in both inpatients and volunteers. Therefore, a removal test of horny cells, adhesion test and down rolling ball (tack) test were all studied to clarify the pharmaceutical characteristics of these preparations. As a result, the score of the skin irritation of the NitrodermTTS® preparation was significantly higher than that for the other two preparations (Antup® and Frandol tape S® preparation).
    No correlations were observed between skin irritation and the amount of horny cells removed by the NitrodermTTS®. The Antup® preparation was the strongest for the adhesion test. However, the NitrodermTTS® preparation was the strongest for the tack test. These findings suggest that one reason for the increased skin irritation of NitrodermTTS® may be due to its high degree tack influence.
  • アミオダロンおよびデスエチルアミオダロンの簡易測定法ならびにその臨床応用, 正置 耕一, 上野 和行, 辻 美里, 平木 精一, 高田 充隆, 鎌倉 史郎, 柴川 雅彦, 病院薬学, 25, 1, 28, 33,   1999年, 10.5649/jjphcs1975.25.28, http://ci.nii.ac.jp/naid/130004299679
    概要:A simple reverse-phase high-performance liquid chromatographic (HPLC) assay for the measurement of amiodarone and its metabolite, desethylamiodarone in the serum was established. The ODS-2 column was used and the absorbance of the effluent from the column at 254 nm was measured. The standard curves for amiodarone and desethylamiodarone were linear up to 5μg/ml. The coefficent of variation (CV) was within 10% at a concentration of 100 ng/ml, and the CV of the intra-and interday variation was within 10% at concentrations of 0.25, 0.5 and 1μg/ml, respectively. These results suggest that the limit of detection is 100 ng/ml for amiodarone and desethylamiodarone, and this assay is thus considered to be a reliable method in clinical practice. On the other hand, the serum amiodarone and desethylamiodarone concentrations were measured in 10 inpatients who received amiodarone for at least 1 month. No significant correlation was observed between the doses and serum drug concentrations. There findings therefore suggest that TDM (Therapeutic Drug Monitoring) should be performed on anyone taking amiodarone.
  • ワルファリンによると考えられる薬剤性肝機能障害の一例, 橋本 博史, 上野 和行, 平木 精一, 高田 充隆, 松尾 汎, 柴川 雅彦, 病院薬学, 25, 1, 60, 64,   1999年, 10.5649/jjphcs1975.25.60, http://ci.nii.ac.jp/naid/130004299684
    概要:A 61-year-old woman weighting 57.9 kg was hospitalized with deep vein thrombosis. She received warfarin therapy. At first 2 mg/day of warfarin was administered for five days while from the 6 th day the dose was increased to 3 mg/day. From the 8 th day the dose was increased to 4 mg/day. Although the GOT and GPT value was within the normal range before the warfarin therapy was started, on the 5 th day after the therapy was started the GOT and GPT levels were 68 and 61 Iu/l, respectively, while on the 12 th day the GOT and GPT had increased even more (99 and 212). We consider such hepatic evidence to be due to the administration of warfarin and its administration was thus stopped. On the 4 th day after warfarin was stopped the GOT and GPT levels decreased to 55 and 128, respectively, and after that it decreased even more. Both the GOT and GPT decreased to the normal range within one month. On the other hand, in order to evaluate an allergy to warfarin, a patch test of warfarin was examined, however, the results of the test was negative. No reports of hepatic failure due to the administration of warfarin could be found on Medline from 1966 to February 1998. These results suggest this case to be a very rare one, however, further study is called for in the future.
  • ジゴキシンの有効治療域内で視覚異常が出現した1症例, 森井 恵, 上野 和行, 高田 充隆, 財田 滋穂, 鎌倉 史郎, 柴川 雅彦, 病院薬学, 24, 6, 683, 686,   1998年12月10日, 10.5649/jjphcs1975.24.683, http://ci.nii.ac.jp/naid/110001799805
    概要:A 65-year-old woman inpatient had been administered methyldigoxin, verapamil and warfarin for the treatment of artrial fibrillation and mitral stenosis disease. About six day after the start of treatment the dose of methyldigoxin was increased from 0.1 to 0.2 mg/day and, as a result, a visual disturbance occurred. However, no other side effects of digoxin were not presented and the serum digoxin concentration was found to be within the normal therapeutic range. The dose was decreased and about five days later, her side effects disappeared. This case suggested that such side effects of digoxin as visual disturbance therefore need to be carfully monitored when ever digoxin and verapamil, which is one of the inhibitors of P-glycoprotein, are coadministered.
  • 国立循環器病センター外来患者における処方薬剤数と年齢の関係, 上野 和行, 井関 淳二, 川副 敦子, 西岡 純子, 橋本 博史, 高田 充隆, 柴川 雅彦, 病院薬学, 24, 6, 745, 749,   1998年12月10日, 10.5649/jjphcs1975.24.745, http://ci.nii.ac.jp/naid/110001799814
    概要:The relationship between the kinds of drugs prescribed and age was investigated in 20990 outpatients (males ; 11,716, females ; 9,274) over the age of twenty at our hospital. No medicines for external application except for patch preparations for ischemic heart disease and injection preparations were caluculated in this studies. The following results were obtained : both preparation for the male and female outpatients increased with age. Although the mean kinds of drugs for patients in their twenties was 2.6, the mean kinds in patients in their eighties was 5.7. In addition, the number of outpatients with diabetes was increased significantly with age than in those without diabetes.
  • 空腹時血糖に及ぼすシベンジリン及びジソピラミド投与の影響, 高田 充隆, 浅田 葉子, 永井 聡子, 柴川 雅彦, 金澤 昭雄, 原納 優, 病院薬学, 24, 5, 541, 547,   1998年10月10日, 10.5649/jjphcs1975.24.541, http://ci.nii.ac.jp/naid/110001799774
    概要:Hypoglycemia has been reported to occur in some patients undergoing treatment with such class la antiarrhythmic drugs as cibenzoline and disopyramide. The changes in the fasting blood sugar (FBS) levels were surveyed in 251 outpatients before and after treatment with cibenzoline and in 416 outpatients before and after treatment with disopyramide at the National Cardiovascular Center from October to November 1996. The FBS before and after treatment with cibenzoline in 43 patients and with disopyramide in 42 patients were thus retrospectively analyzed. Cibenzoline treatment significantly reduced the FBS level (from 98.6±14.2 to 92.1±17.0 mg/dl, p< 0.05), whereas disopyramide treatment did not significantly change the FBS level. Furthermore, in patients receiving cibenzoline treatment, a significant reduction of the FBS was also observed in elderly patients (>65 years), in patients receiving high doses (>300 mg/day), and in patients with a reduced renal function (BUN : >20 mg/dl or Scr : M>1.3, F>1.0 mg/dl). These results suggest that close attention should thus be paid to the occurrence of cibenzoline-induced hypoglycemia in eiderly patients, those receiving high doses and those with a reduced renal function.
  • 13P-6-02 シベンゾリンの薬物動態に関する研究, 西岡 純子, 上野 和行, 高田 充隆, 柴川 雅彦, 日本病院薬学会年会講演要旨集, 8,   1998年08月17日, http://ci.nii.ac.jp/naid/110001267526
  • ジゴキシンの有効治療域内で視覚異常が出現した1症例, 森井 恵, 上野 和行, 高田 充隆, 財田 滋穂, 鎌倉 史郎, 柴川 雅彦, 病院薬学, 24, 6, 683, 686,   1998年, 10.5649/jjphcs1975.24.683, http://ci.nii.ac.jp/naid/130004299659
    概要:A 65-year-old woman inpatient had been administered methyldigoxin, verapamil and warfarin for the treatment of artrial fibrillation and mitral stenosis disease. About six day after the start of treatment the dose of methyldigoxin was increased from 0.1 to 0.2 mg/day and, as a result, a visual disturbance occurred. However, no other side effects of digoxin were not presented and the serum digoxin concentration was found to be within the normal therapeutic range. The dose was decreased and about five days later, her side effects disappeared. This case suggested that such side effects of digoxin as visual disturbance therefore need to be carfully monitored when ever digoxin and verapamil, which is one of the inhibitors of P-glycoprotein, are coadministered.
  • 13-5-10 Disopyramide 及び Cibenzoline の空腹時血糖に及ぼす影響, 浅田 葉子, 永井 聡子, 高田 充隆, 柴川 雅彦, 金澤 昭雄, 原納 優, 日本病院薬学会年会講演要旨集, 7,   1997年08月15日, http://ci.nii.ac.jp/naid/110001266899
  • 関西地区の病院に勤務する薬剤師の職業意識調査, 村上 悦子, 川畑 篤史, 岩城 正宏, 小木曽 太郎, 鈴木 茂生, 小田 泰雄, 黒田 良太郎, 掛樋 一晃, 三島 正彦, 高田 充隆, 薬学総合研究所紀要, 6, 93, 103,   1997年, http://ci.nii.ac.jp/naid/110000560682
  • 入選論文 (MHフォ-ラム懸賞論文「医薬品の適正使用への病院薬剤師の貢献」), 高田 充隆, 月刊薬事, 38, 8, 2039, 2042,   1996年07月, http://ci.nii.ac.jp/naid/40001041285
  • 血中アプリンジン濃度測定における蛍光偏光免疫測定法の評価, 高田 充隆, 福井 啓祐, 小林 雅典, 大石 輝樹, 川本 忠正, 山本 雅彦, 河南 昌樹, 松山 榮一, 臨床薬理, 20, 1, 195, 196,   1989年, 10.3999/jscpt.20.195, http://ci.nii.ac.jp/naid/130002046497
  • 血中アプリンジン濃度測定における螢光偏光免疫測定法の評価, 高田 充隆, 福井 啓祐, 小林 雅典, 渡辺 幸野, 川本 忠正, 山本 雅彦, 病院薬学, 14, 4, 256, 261,   1988年08月20日, 10.5649/jjphcs1975.14.256, http://ci.nii.ac.jp/naid/110001798547
    概要:The fluorescence polarization immunoassay (FPIA) method for the determination of serum aprindine (AP) concentrations was evaluated by comparison with HPLC method. The within-run precision of FPIA method was 4.6-6.8% as the coefficient of variation (C.V.). The C.V. value of between-run precision was 4.1-8.7%. The values of serum AP concentrations determined by FPIA method correlated well with those determined by HPLC method. The correlation coefficient was 0.987. FPIA method, reliable, simple and rapid, seems to be a useful method for routine clinical use.
  • 血中アプリンジン濃度測定における蛍光偏光免疫測定法の評価, 高田 充隆, 福井 啓祐, 小林 雅典, 渡辺 幸野, 川本 忠正, 山本 雅彦, 病院薬学, 14, 4, 256, 261,   1988年, 10.5649/jjphcs1975.14.256, http://ci.nii.ac.jp/naid/130004894596
    概要:The fluorescence polarization immunoassay (FPIA) method for the determination of serum aprindine (AP) concentrations was evaluated by comparison with HPLC method.The withinrun precision of FPIA method was 4.6-6.8% as the coefficient of variation (C. V.).The C.V. value of between-run precision was 4.1-8.7%.The values of serum AP concentrations determined by FPIA method correlated well with those determined by HPLC method.The correlation coefficient was 0.987.FPIA method, reliable, simple and rapid, seems to be a useful method for routine clinical use.
  • リパーゼ活性におよぼす胆汁酸製剤の影響, 高田 充隆, 村上 博美, 赤野 威彦, 野口 利明, 小早川 清, 河原 勉, 病院薬学, 11, 5, 387, 391,   1985年10月20日, 10.5649/jjphcs1975.11.387, http://ci.nii.ac.jp/naid/110001798127
    概要:The effects of chenodeoxycholic acid (CDCA) and ursodeoxycholic acid (UDCA) on enzymic activity of lipase, as well as the relationship between the lipase activity and the concentration of bile acids in bile, were studied. In the presence of bile administered CDCA, the lipase activity was enhanced significantly. A correlation between the lipase activity and the common logarithm of the concentration of total bile acid and CDCA in bile was observed, correlation coefficients being 0.723 (n=30) and 0.732 (n=30), respectively. In addition, it was observed from the result of multiple regression that CDCA and UDCA increased the lipase activity.
  • L-ケフレックスの有効血中濃度持続化におよぼす食餌因子の影響, 上野 和行, 森田 俊彦, 高田 充隆, 中多 泉, 福井 澄夫, 尾崎 照美, 病院薬学, 9, 1, 53, 56,   1983年02月20日, http://ci.nii.ac.jp/naid/110001797138
    概要:L-Keflex is a sustained-release preparation of cephalexin (CEX). It is composed of non-enteric coated granules and enteric coated ones at the potency ratio of 3 to 7. The effect of food on the prolonged activity of L-Keflex was investigated in six volunteers by a cross-over method. 1000 mg of L-Keflex was orally administered to the volunteers after usual meal or light meal. The followings are the results of the study : In both groups of usual and light meals, L-Keflex level of more than 3.13 μg/ml in serum lasted for about 8 hours. However, the serum level pattern in the light meal group was apparently different from that in the usual meal group. The former group showed 2 peaks of serum levels, whereas the latter one gave only a single peak.
  • L-ケフレックスの有効血中濃度持続化におよぼす食餌因子の影響, 上野 和行, 森田 俊彦, 高田 充隆, 中多 泉, 福井 澄夫, 尾崎 照美, 病院薬学, 9, 1, 53, 56,   1983年, http://ci.nii.ac.jp/naid/130004299953
    概要:L-Keflex is a sustained-release preparation of cephalexin (CEX). It is composed of non-enteric coated granules and enteric coated ones at the potency ratio of 3 to 7. The effect of food on the prolonged activity of L-Keflex was investigated in six volunteers by a cross-over method. 1000 mg of L-Keflex was orally administered to the volunteers after usual meal or light meal. The followings are the results of the study: In both groups of usual and light meals, L-Keflex level of more than 3.13μg/ml in serum lasted for about 8 hours. However, the serum level pattern in the light meal group was apparently different from that in the usual meal group. The former group showed 2 peaks of serum levels, whereas the latter one gave only a single peak.
  • 高速液体クロマトグラフによるFAD注射剤の比較検討, 平野 善信, 田中 義一, 長谷川 健次, 橋爪 昭人, 高田 充隆, 中多 泉, 佐用 雅弘, 丹尾 長与, 病院薬学, 8, 2, 133, 137,   1982年06月20日, http://ci.nii.ac.jp/naid/110001796922
    概要:Eight types of the commercial FAD injection were studied from the pharmaceutical viewpoint with high-performance liquid chromatography (HPLC). It was found that most of the commercial FAD injections had lower content of FAD than their labeled amount. FAD was detected from the HPLC peaks whether it is manufactured by synthetic method or fermentation method.
  • 高速液体クロマトグラフによるFAD注射剤の比較検討, 平野 善信, 田中 義一, 長谷川 健次, 橋爪 昭人, 高田 充隆, 中多 泉, 佐用 雅弘, 丹尾 長与, 病院薬学, 8, 2, 133, 137,   1982年, http://ci.nii.ac.jp/naid/130004103315
    概要:Eight types of the commercial FAD injection were studied from the pharmaceutical viewpoint with high-performance liquid chromatography (HPLC). lt was found that most of the commercial FAD injections had lower content of FAD than their labelled amount. FAD was detected from the HPLC peaks whether it is manufactured by synthetic method or fermentation method.
  • 消化酵素剤のリパーゼ活性におよぼす胆汁酸の影響, 高田 充隆, 佐藤 信, 橋爪 昭人, 平野 善信, 尾崎 照美, 病院薬学, 7, 5, 265, 268,   1981年12月20日, http://ci.nii.ac.jp/naid/110001796878
    概要:It has been widely known that bile acids increase lipase activity, and the lipase activity of various digestive enzyme preparations has been reported. Clinically, bile acids have often been administered in combination with digestive enzyme preparations. In this study, effects of three bile salts (sodium ursodesoxycholate, sodium chenodesoxycholate and sodium dehydrocholate) on the lipase activity of digestive enzyme preparations were examined. When soybean oil emulsified by polyvinyl alcohol was used as a substrate, these bile salts increased their lipase activity. In the presence of sodium chenodesoxycholate, sodium ursodesoxycholate and sodium dehydrocholate, digestive enzyme preparations increased their lipase activity by 2.2, 1.5 and 1.3 times, respectively, stronger than that in the absence of these bile salts. When soybean oil was used as a substrate, only sodium chenodesoxycholate increased the lipase activity.
  • 消化酵素剤のリパーゼ活性におよぼす胆汁酸の影響, 高田 充隆, 佐藤 信, 橋爪 昭人, 平野 善信, 尾崎 照美, 病院薬学, 7, 5, 265, 268,   1981年, http://ci.nii.ac.jp/naid/130004299914
    概要:It has been widely known that bile acids increase lipase activity, and the lipase activity of various digestive enzyme preparations has been reported. Clinically, bile acids have often been administered in combination with digestive enzyme preparations. In this study, effects of three bile salts (sodium ursodesoxycholate, sodium chenodesoxycholate and sodium dehydrocholate) on the lipase activity of digestive enzyme preparations were examined. When soybean oil emulsified by polyvinyl alcohol was used as a substrate, these bile salts increased their lipase activity. In the presence of sodium chenodesoxycholate, sodium ursodesoxycholate and sodium dehydrocholate, digestive enzyme preparations increased their lipase activity by 2.2, 1.5 and 1.3 times, respectively, stronger than that in the absence of these bile salts. When soybean oil was used as a substrate, only sodium chenodesoxycholate increased the lipase activity.